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ABSTRACT: MOLECULAR MECHANISMS UNDERLYING ALCOHOL USE 
DISORDER AND MAJOR DEPRESSIVE DISORDER COMORBIDITY 
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The University of Texas at Austin, 05/2017 
 
 
Supervisors: R. ADRON HARRIS and KIMBERLY RAAB-GRAHAM 
 
Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD) are two 
widespread and debilitating disorders that share a high rate of comorbidity with 
the presence of either disorder doubling the risk of developing the other. Despite 
their prevalence, few treatments are available to individuals with comorbid AUD 
and MDD. Both alcohol and antidepressants promote lasting neuroadaptive 
changes in synapses and dendrites. With alcohol these changes may provide 
relief from depressive symptoms, and the initial use of alcohol may be a form of 
self-medication for individuals with MDD, suggesting ethanol may have 
antidepressant properties underlying similarities in neurobiological abnormalities. 
However, the synaptic pathways that are shared by alcohol and antidepressants 
are unknown. This study aims to identify why acute exposure to ethanol 
produced lasting antidepressant and anxiolytic behaviors. To understand the 
functional basis of these behaviors, a molecular pathway activated by rapid 
antidepressants was investigated. Here ethanol, like rapid antidepressants, 
altered γ-aminobutyric acid type B receptor (GABABR) expression and signaling, 
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to increase dendritic calcium. New GABABRs were synthesized in response to 
ethanol treatment, requiring fragile-X mental retardation protein (FMRP). Ethanol-
dependent changes in GABABR expression, dendritic signaling, and 
antidepressant efficacy were absent in Fmr1-knockout (KO) mice. These findings 
indicate that FMRP is an important regulator of protein synthesis following acute 
alcohol exposure, and provided a molecular basis for the antidepressant efficacy 
of acute ethanol exposure. We identify alterations on a global scale with acute 
alcohol and antidepressant by sequencing the synaptic transcriptome. We 
identified parallel alterations in exon usage with acute alcohol and antidepressant 
treatment. These shared differentially expressed exons may give rise to isoforms 
and proteins with altered function or localization in the synapse. Some of these 
differentially expressed exons were identified in genes known to have alternative 
isoforms with AUD and MDD. These data implicate alternative splicing and 
isoform expression in the acute antidepressant-like effects of ethanol and the 
development of comorbid alcohol and depression. Understanding the molecular 
basis for comorbidity may aid in development of treatment options for afflicted 
individuals with dual disorders, as well as explore the mechanism for the initiation 
of addiction with acute exposure to alcohol.   
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CHAPTER 1: INTRODUCTION 
Disease overview 
Alcohol use disorder and major depressive disorder are two wide spread and 
devastating disorders which often occur together. It is evident that a high rate of 
comorbidity occurs between these disorders, but how and why they develop 
together is an unanswered question. Alcohol abuse, depression, and evidence of 
comorbidity will be discussed in this section.  
Alcohol Use Disorder 
 
Alcohol use disorder (AUD) is the medical diagnosis given to individuals with 
severe problem drinking. AUD affects approximately 7% of adults in the United 
States, which includes about 11 million men and 6 million women. It is one of the 
world’s leading health risks causing more than 60 major types of diseases and 
injuries, and resulting in approximately 3.3 million deaths each year or 5.9% of all 
deaths globally. Alcohol can cause harm and death through its toxic effect on 
organs and tissues; ability to cause impairment in physical coordination, 
consciousness, perception, and cognition leading to accidental injury or death to 
self or others; and reduces self-control affecting a persons behavior (WHO 2014 
global status report).  
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The addictive nature of alcohol is due in part to neuroadaptive changes 
that occur in response to chronic ethanol exposure (Fig. 1.1). Neuroadaptation 
alters brain functioning to compensate for constant exposure to alcohol making it 
difficult for individuals to function in its absence. Neuroadaptation from continued 
alcohol abuse manifest as tolerance and physiological dependence, and are 
thought to be crucial to transition from controlled drinking to frequent, 
uncontrolled and excessive drinking1. Remodeling of the synapse in response to 
alcohol is thought to lead to tolerance and physical dependence in AUD2. The 
initial signaling mechanisms that produce changes in synaptic protein 
composition that lead to neuroadaptations have yet to be explored, but it appears 
to be a slippery slope that initiates acute changes that with repeated exposure 
can lead to addiction. AUD is also a difficult disorder to overcome once 
diagnosed in an individual due to alcohol withdrawal complications. Withdrawal 
symptoms can be dangerous and last for prolong periods of time. Symptoms 
including: seizures, vomiting, hallucinations, and autonomic hyperactivity. 
Withdrawal symptoms can also make individuals relapse even after periods of 
abstinence, perpetuating alcohol use and abuse3. The widespread and 
debilitating nature of AUD make the development of more effective treatment 
options imperative.  
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Figure 1.1. Cycle of Alcohol Dependence 
 
Schematic illustrating how acute drinking can develop into alcohol dependence 
due to neuroadaptation, which in turn causes withdrawal symptoms with alcohol 
abstinence and enhanced vulnerability to relapse. Altered synaptic protein 
composition and plasticity with alcohol exposure may be involved in the initial 
changes that lead to problem drinking and neuroadaptation/dependence. 
Synaptic plasticity may also be involved in reversing the effects of 
neuroadaptation with abstinence/withdrawal. 
 
Available pharmacological treatments 
 
Currently there are minimal effective pharmacological treatments for AUD, 
because AUD is a complex disorder affecting many brain regions and cellular 
pathways. The most common drugs used to treat chronic alcohol use are 
Acute Drinking
Problem/Abusive Drinking
Alcohol Dependence
Uncontrollable/Excessive Drinking
Abstinence
Acute Withdrawal
Relapse
Altered Synaptic Plasticity
Neuroadaptation
Altered Synaptic Plasticity
or
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Disulfiram, Naltrexone, and Acamprosate, however there are other available 
drugs to address symptoms such as benzodiazepines for withdrawal.  
 Disulfiram has been used for over 50 years and is FDA approved for the 
treatment of alcoholism. Its mechanism of action causes the natural breakdown 
of alcohol to produce acetaldehyde, which can be toxic and causes aversive 
reactions when alcohol is consumed such as vomiting, headache, and anxiety4. It 
acts as a deterrent to drinking for individuals to whom it is administered, however 
it is difficult for individuals to maintain compliance due to these side effects. In 
some cases it may also induce psychiatric disorders such as delirium, 
depression, anxiety, psychosis, and mania. There is little information about the 
effects of Disulfiram in individuals with comorbid disorders4.  
 Naltrexone is also FDA approved for the treatment of AUD and its mode of 
action is to block the action of ethanol induced chemical signals in the brain from 
opioids. It has been shown to be effective in treating alcohol dependence in 
humans, and reported to lower levels of alcohol craving and drinking5. Naltrexone 
is a promising treatment of comorbidity with psychiatric disorders however more 
research is needed. However, Naloxone a similar opioid antagonist, 
demonstrated no effect on mood in patients with depression6.  
 Lastly Acamprosate is promising in the treatment of AUD and is FDA 
approved for such a purpose. Acamprosates mode of action is not completely 
understood but is thought to normalize alcohol-disrupted brain activity through 
GABA and glutamate neurotransmission7. Acamprosate may help individuals 
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with AUD achieve abstinence and diminish withdrawal symptoms8. Symptoms of 
alcohol and psychiatric disorder comorbidity with Acamprosate still need to be 
studied, although it has been shown to have some positive effects in patients 
with comorbid schizophrenia9. However, Acamprosate may increase suicide rate 
with long-term use10.  
 Various pharmacological avenues for aiding patients with AUDs have 
been developed. However issues with existing treatments include side affects, 
lack of patient compliance, and effectiveness of the drugs with comorbid 
psychiatric disorders, which is incredibly high in patients with AUDs. Therefore, 
novel treatment strategies that reduce adverse effects and are applicable across 
common comorbidities warrant development. 
Major Depressive Disorder 
 
Major Depressive Disorder (MDD) is a widespread and debilitating mental 
disorder effecting approximately 350 million people worldwide. In the United 
States it will effects about 17% of individuals at some point in their lifetime11. 
Depression can become a serious long-lasting health risk. Depression can result 
in suffering for the patient and individuals involved with the patient, through an 
inability to preform daily functions such as caregiving and working. In severe 
cases depression can lead to suicide. More than 800 thousand people die each 
year to suicide (WHO global status report).  
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MDD symptoms can include: depressed mood, irritability, loss of pleasure 
or interest, reduced energy, and diminished activity, anxiety symptoms, disturbed 
sleep, appetite or weight change, poor concentration, and low self-worth, 
depending on the severity of the episode which can last two weeks or 
more12(WHO global status report). MDD can interfere and impair with a patients 
relationships, school or work, stress levels and anxiety and daily activity12. 
Current pharmacotherapies for depression can take weeks to become effective 
and many individuals are treatment resistant, leaving these people susceptible to 
self-destructive behavior and suicide13. Self-medication with drugs and alcohol 
can also become an issue, as well as comorbidity to other disorders14.  
 The exact cause of MDD is unknown, but certain factors increase the risk 
of developing the disorder. Factors such as genes and stress can affect brain 
chemistry and alter mood stability, and changes in hormone balance may 
contribute to MDD development12,14. Additionally external factors can trigger 
MDD such as alcohol and drug abuse, medical illness like hypothyroidism and 
cancer, other psychiatric disorders such as bipolar disorder, some medications 
like steroids, and bereavement12, 15. The widespread, complex, and poor 
treatment options for MDD makes it imperative to research this disorder to find 
alternative treatment options and to investigate its relationship to other 
debilitating disorders. 
Available pharmacological treatments 
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The most common pharmacological treatments for MDD are selective serotonin 
reuptake inhibitors (SSRIs) and tricyclic or tetracyclic antidepressants (TCAs). 
SSRIs mode of action block the reuptake of serotonin increasing availability of 
serotonin in synaptic cleft and brain16. There are several FDA approved SSRI to 
treat depression including Citalopram (Celexa), Fluoxetine (Prozac), Paroxetine 
(Paxil), Escitalopram (Lexapro), and more. SSRIs have few serious side effects, 
and are the most popular antidepressant used to treat humans16. However, 
SSRIs only alleviate symptoms of MDD in 37% of patients treated17. In addition 
to its affects on MDD, SSRIs have been found to affect alcohol consumption. 
SSRIs may aid individuals with comorbid AUD by decreasing consumption and 
preventing relapse with stress18. SSRIs were also shown to be effective in 
reducing alcohol use in individuals with MDD but not without, reducing symptoms 
of AUD and MDD in comorbid patients19, 20. 
TCAs are the second choice for treating patients with antidepressants as 
they have more side effects and potential for overdose, but are still effective in 
treating MDD21. TCAs ease depression symptoms by acting on neurotransmitters 
to regulate brain chemistry. They have a complex pharmacological profile and 
inhibit multiple neurotransmitter reuptake sites including the reuptake of serotonin 
and norepinephrine to increase levels at the synaptic cleft21. Examples of FDA 
approved TCAs include: Impiramine (Tofranil), Desipramine (Norpramin), 
Doxepin, Protriptyline (Vivactil), and more. TCAs have also been shown to treat 
depression in patients with comorbid AUD22. 
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These conventional antidepressant treatments work well for some, but a 
majority of patients with MDD are resistant to these drugs and find little or no 
relief from them. Additionally, these drugs can take weeks to decrease MDD 
phenotypes and leave patience vulnerable to self-harm and suicide during this 
time, as well as impeding on daily activities23, 24. In addition to these standard 
antidepressant treatments a new class of antidepressants has developed that are 
rapid acting and have lasting antidepressant behavioral responses.  
Rapid acting antidepressants (RAADs) were first identified in the early 
1990s to inhibit N-methyl-D-aspartate receptor (NMDAR) activity and promote 
antidepressant phenotypes25. RAADs such as ketamine elicit an antidepressant 
response by antagonizing NMDARs and engage a cascade of events that 
includes a surge in glutamate, stimulation of AMPAR and activation of mTOR 
signaling and synaptic formation25, 26. Examples include Ketamine, Ro 25-6981, 
MK-801, and AP5. Ketamine, and other FDA approved NDMAR antagonist have 
remarkable efficacy in treating conventional drug resistant depression, however 
they also have a downside. The addictive nature and side effects of some 
RAADs make them less desirable for pharmacotherapy and therefore finding 
alternative drugs is imperative27. Atypical NDMAR antagonists specific for the 
NR2B subunit were discovered to have improved side effects28-30, making 
characterization of other NR2B selective antagonists desirable for possible new 
treatments31.  Ro 25-6981 (Fig. 1.2) is one of these antagonists studied as an 
alternative to Ketamine due to Ketamine’s undesirable side effects29. Ro 25-6981 
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is a noncompetitive allosteric modulator of the NR2B subunit of NMDARs, and is 
potent and highly specific for NR2B blocking NMDARs containing this subunit31, 
32 33. Ro 25-6981 has a slow half-life of dissociation, reported to last greater than 
5 hours at 4oC, and inhibits in a concentration dependent manner with high 
potency at a Ki of 20nM31. It is an activity-dependent inhibitor, binding with higher 
affinity to the activated and desensitized receptor32.  In this study we chose to 
use Ro 25-6981 as a novel rapid-antidepressant specific for NR2B antagonism34. 
 
Figure 1.2. Chemical structure of Ro 25-6981  
(αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol.  
 
Comorbidity 
 
AUD often accompanies other mental disorders, some of which are thought to 
display aberrant synaptic plasticity35. The mechanism underlying the linkage 
between AUD and MDD is not well understood, but the presence of either 
disorder in an individual doubles the risk of developing the other disorder14, 36. 
Additionally, AUD and MDD are among the leading cause of disability in the 
world14. Individuals with AUD comorbid MDD have an earlier onset of alcohol 
dependence and increased rates of lifetime drug dependence37.  Comorbid MDD 
N
OH
HO
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patients entering treatment for alcohol and drug addiction tend to have worse 
outcomes than those without dual diagnosis38 including higher relapse rates39. 
Comorbidity is also associated with greater severity and number of both suicide 
attempts and completed suicides20, 40.  
Epidemiological and clinical studies both support the notion that AUD and 
MDD are closely linked. AUD and MDD may be caused by similar environmental 
and genetic factors14, 36. One hypothesis suggests that depressed individuals 
self-medicate with alcohol. This may decrease depressive symptoms acutely, but 
consistent alcohol abuse may lead to addiction and development of AUD. 
Therefore, self-medicating with alcohol may also play a role in the development 
of AUD in individuals with MDD14, 41. 
Treatment failure for co-occurring AUD and MDD might be explained by 
the theory that patients with comorbidity often do not receive specialized 
treatment for both conditions. Pharmacological and psychosocial treatments are 
available for each disorder, but need to be integrated to help comorbid patients, 
and few established treatments for psychiatric disorders have been evaluated in 
patients with dual AUD18. Additionally, individuals with an AUD and co-occurring 
psychiatric disorder such as depression may find it more difficult to access and 
participate in traditional alcohol treatments, which require patient compliance, 
and self-help groups where most members do not have comorbid disorders19, 42. 
Interestingly, treatment of AUD has been shown to reduce MDD symptoms and 
vise versa14. Specifically the rapid antidepressant Ketamine can has been 
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observed to reduce ethanol seeking behavior, and NMDAR antagonism may 
decrease ethanol intake by substituting alcohol and acting as a reinforcing 
stimulus43. More research is necessary for treatment for comorbid patients due to 
the complexity of the overlapping symptoms, common neurobiological 
abnormalities and limited dual treatment options. 
Molecular Mechanisms 
Alcohol and Antidepressants alter a vast and varied array of molecular and 
cellular processes, and this material is added to continuously. Discussed here 
are most well known modes of action of alcohol and antidepressants. Particular 
interest is placed on synaptic pathways and proteins important to the body of 
work presented in this dissertation.  
Acute Alcohol 
 
Acute ethanol exposure can affect the function of ion channels, neurotransmitter 
receptors, and intracellular signaling proteins. Ion channels are one of the most 
well studied targets of ethanol action. In particular ligand-gated ion channels bind 
neurotransmitters or intracellular messengers to activate and open an intrinsic 
ion pore. In general ethanol exposure facilitates the function of ligand gated ion 
channels including nicotinic acetylcholine and serotonin receptors, GABAAR, and 
strychnine sensitive glycine receptors44, 45. Ethanol is thought to increase the 
probability of the opening of some channels and/or increase agonist affinity46, 47, 
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such as when ethanol increases amplitude and duration of GABAAR and Glycine 
(GlyR) mediated inhibitory postsynaptic currents (IPSCs)48, 49, which is though to 
increase neuronal inhibition. Acute ethanol exposure also potentiates 5-HT3 
receptors function45.  
 Effects of acute ethanol exposure on ionotropic glutamate receptors have 
also been well studied. These ionotropic glutamate receptors (iGluRs) include 
AMPA, NMDA, and Kainate receptors. These glutamate receptors are generally 
inhibited by ethanol50. The best-characterized pathway is ethanol’s inhibition of 
NMDR. NMDAR is a ligand, voltage-gated cation channel known for its role in 
shaping synaptic strength during synaptic plasticity51. Ethanol inhibits NMDAR 
function in a concentration dependent manner at ranges that produces 
intoxication52. Interestingly, synaptic responses mediated by NMDARs have been 
shown to decrease with acute ethanol exposure45, 53-55. NMDARs are heteromeric 
proteins, with an obligatory NR1 subunit and one or more NR2 subunits 56, 57. 
NMDAR receptors containing an NR2B subunit are particularly sensitive to 
ethanol’s effects58. Importantly, Ro 25-6981 is selective for the NR2B subunit of 
NMDAR, binding noncompetitively to a domain of NR2B that promotes 
stabilization and a closed conformation of the receptor32. Ethanol inhibition of 
these glutamate receptors generally reduces neuronal excitability in most brain 
regions by reducing excitatory synaptic drive and preventing synaptic plasticity 
that is dependent upon iGluR activity45. Ethanol has been shown to attenuate 
NMDA induced ion currents in cultured hippocampal neurons and slices, and that 
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antagonism of NMDAR mediated activity by ethanol may attenuate memory 
related synaptic plasticity in the hippocampus59.  
The hippocampus is thought to be critically involved in addiction in 
humans, particularly in synaptic plasticity necessary for drug associated learning 
and memory60. Ethanol related memory retrieval was also observed to cause 
synaptic protein synthesis, and disruption of these memories by mTORC1 
inhibition prevented relapse61. MTORC1 is activated by ethanol and is a protein 
essential to mediating signaling pathways required for local dendritic/synaptic 
proteins associated with synaptic plasticity and memory processes61, 62. These 
studies indicate that acute ethanol exposure is involved in synaptic plasticity 
related pathways.  
 In addition to ionotropic receptors, ethanol also affects G protein-coupled 
receptors (GPCRS). GPCRs are receptors specialized in binding 
neurotransmitters and initiating intracellular signaling pathways. GPCRs can 
affect neurophysiology by indirectly altering protein kinases, ion channels, 
intracellular signaling, and gene expression down stream. Ethanol inhibits activity 
of the metabotropic glutamate receptors, Acetylcholine receptors (Ach) and 
serotonin type 2 receptors. Inhibition to these GPCRs is most likely a 
downstream effect of ethanol target sites63, 64. However it is thought that ethanol 
weakly affects these protein and their physiologic impact is not yet clear45. 
Ethanol can also potentiate the function of G protein-coupled inwardly-rectifying 
potassium channels (GIRKs) at intoxicating concentrations65-67. GIRKs are 
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inwardly-rectifying potassium ion channels that through GPCR signaling open 
and induce hyperpolarization. GIRK channels usually inhibit neuronal activity by 
hyperpolarizing neurons, and ethanol effects on GIRK2 channels may contribute 
to intoxication67.  
Neurotransmitters are also affected by ethanol. Monoamine levels in brain 
increase with acute ethanol exposure68, and GABA release increases although 
no change in glutamate occurs69.  However most neurotransmitter transporters 
are relatively insensitive to acute ethanol. Acute ethanol exposure has numerous 
effects on neurons and signaling cascades, and those discussed are only the 
best studied and relevant. Additional research is required to expand our 
knowledge of the vast array of effects that ethanol exposure induces as well as 
understand how these alterations affect individuals on molecular and behavioral 
levels. 
Rapid-Antidepressants 
 
Ketamine, Ro 25-6981, and other FDA approved NDMAR antagonist have 
remarkable efficacy in treating conventional drug resistant depression. NMDAR 
blockade at rest is known to cause antidepressant behavioral responses70. Acute 
treatment with Ketamine or Ro 25-6981 can relieve depression symptoms as well 
as stress induced anhedonia, and anxiogenic behaviors71. RAADs ability to 
alleviate depression quickly and remain effective for long periods is due to their 
capacity to engage homeostatic mechanisms that trigger protein synthesis 
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pathways25. RAADs can remain in effect long after the drug has cleared the 
patients system due in part to altered synaptic plasticity and synaptogenesis 
induced through NMDAR inhibition72-74. Acute doses engage numerous synaptic 
signaling mechanism that can induce protein synthesis and increase synaptic 
connections long-term, possibly reestablishing brain activity levels that remedy 
depressed systems75.  
Ketamine has been shown to activate synaptic protein synthesis in an 
mTOR dependent manner. Increased mTOR activity with NMDAR blockade 
increases synaptic signaling proteins and the number and function of neuronal 
spines. Blocking mTOR inhibits ketamine induction of synaptogenesis and 
antidepressant behavioral responses76. Similar to ketamine the rapid-
antidepressant Ro 25-6981 inhibits NMDAR activity, however unlike ketamine it 
is specific for the NR2B receptor subunit77. Ro 25-6981 is an effective rapid-
antidepressant as determined by numerous behavioral studies13, 76, 78, and has 
been shown to mimic some molecular and behavioral phenotypes of alcohol79. 
Synaptic Plasticity and Neuroadaptation 
 
Changes in the efficacy of synaptic signaling contribute to many aspects of 
development in brain, learning and memory, and addiction80. Synaptic plasticity 
allows synapses to adjust the efficacy of synaptic transmission, strengthening or 
weakening, in response to synaptic activity and stimulation. Synaptic plasticity 
commonly manifests in the form of long-term potentiation (LTP), and long-term 
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depression (LTD). In general, LTP increases synaptic transmission and LTD 
decreases synaptic transmission. LTP and LTD are induced by repetitive 
patterns of activation or inputs to a postsynaptic neuron54. Acute ethanol 
exposure suppresses the induction of LTP at synapses54.  
Synaptic plasticity induces changes in protein composition of synapses 
through local protein translation81, 82. mRNAs, and their associated binding 
proteins or miRNAs, have been shown to be transported from the cell body to 
dendrites in response to synaptic activity 83,84,85. Regulation of localization is 
thought to occur through cis-acting localization elements of the 3’-untranslated 
region (3’-UTR) of mRNA and RNA binding proteins81, 86. Various RNA binding 
proteins regulate translation and modulate both localization and translation of 
mRNAs with related functions, such as the Fragile-X mental retardation protein 
(FMRP)87-89. Increasing evidence indicates mRNA localization and translation are 
tightly linked and regulated90. After localization mRNAs are translated in 
synapses in response to synaptic stimulation by polyribosomes at the base of 
spines91. Individual synapses could independently regulate morphology in a 
protein synthesis dependent manner in response to stimuli81. mRNA localization 
and translation provides a general mechanism whereby neurons can locally alter 
protein composition within discrete subcellular compartments92. 
Changes in signaling and neuronal plasticity may be critical components in 
development of lasting ethanol behavioral phenotypes such as dependence, 
sensitization, and craving93. Transcriptional profiling has been explored acutely to 
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understand the initial steps that may lead to neuroadaptation. Previous studies 
have identified that synaptoneurosomes collected from chronic drinking mice had 
a greater number of alcohol responsive mRNAs and higher fold changes as 
compared to the total homogenate when sequenced94. We have previously 
identified molecular changes in synaptoneurosomes and dendrites with ethanol 
and Ro 25-698113, 78, 79. Other rapid-antidepressants such as ketamine have also 
been shown to effect changes in mRNA at synapses and synaptic plasticity. 
Ketamine facilitates neuronal plasticity in brain regions implicated in MDD95. 
Interestingly, Ro 25-6981 may have similar effects due to their relatively 
conserved mechanism of action78. Both ethanol and antidepressants have been 
shown to inhibit NMDARs and facilitate translation of synaptic proteins and 
synaptic plasticity in an mTORC1 dependent manner74, 96. MTOR can be 
regulated by upstream NMDAR activated pathways97, and mTOR pathways are 
known to promote local protein synthesis55, 98. In neurons mTOR can be activated 
by calcium signaling through PI3Kinase and its activity can promote cap-
dependent translation by phosphorylating S6 Kinase (S6K) and eIF4E binding 
protein (4E-BP) to initiate translation99, 100. Ethanol and RAADs share some 
similarities in these pathways and they may underlie a shared antidepressant 
effect between Ethanol and RAADs.   
Neuroadaptation can arise from repeated exposure to drugs or chronic 
drug abuse. Neuroadaptation arises when lasting changes in neurons such as 
synaptic protein composition occur to adapt and counter the effects of exposure 
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to chemicals such as alcohol. With repeated exposure of drug, lasting changes in 
synaptic plasticity may develop and give rise to addiction. These initial changes 
in synaptic plasticity with acute exposure have not been fully explored93, 101.  
 
The GABAB Receptor Shift 
 
GABABRs are G-protein coupled receptors that are typically responsible for 
depressing neuronal activity101, 102. GABABRs decrease neurotransmitter release, 
inhibit presynaptic calcium channels, and activate slow inhibitory postsynaptic 
potassium channels. The GABAB Receptor is a heterodimer comprised of two 
subunits of GABABR1 and GABABR2. This receptor has a long extracellular 
amino terminus, seven transmembrane domains and a short intracellular carboxy 
terminus responsible for linking the subunits. GABABR2 functions as a carrier to 
GABABR1, transporting GABABR1 from the endoplasmic reticulum to the cell 
membrane. GABABRs are localized to most brain regions and are at high 
concentrations in the hippocampus. GABABRs are metabatropic receptors and 
transmit intracellular signals via adaptor proteins capable of producing functional 
changes including effects on intracellular enzymes and ion channels. These 
secondary messenger systems operate through binding and activation of 
guanine nucleotide binding proteins or G proteins. Of particular interest, GABABR 
activation can induce GIRK channels and block Ca2+ influx through voltage 
dependent calcium channels. GABABR are generally thought to be inhibitory and 
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reduce calcium signaling pathways102, 103. Some evidence also suggests that 
GABABR function may alter alcohol-drinking behaviors104, 105, but further research 
is needed to understand the role of GABABRs and alcohol dependence.  
Recently GABABRs have been identified to have an alternative function 
when NMDARs are inhibited in dendrites and synapses (Fig. 1.3). This shift in 
GABABR function is induced when NMDARs are blocked by the rapid 
antidepressant Ro 25-6981, AP513, and ethanol79. Introduction of an NMDA 
antagonist was demonstrated in mice and cultured hippocampal neurons to 
induce new dendritic synthesis of GABABR2, increases formation of new 
GBABARs. These new GABABRs operate outside of their canonical role of 
activating potassium channels and instead shift function to promote dendritic 
calcium entry. GABABR-facilitated increases in dendritic calcium promotes a 
signaling cascade leading to heightened mTOR activity and mTOR dependent 
translation of plasticity-related proteins that may produce neuroadaptations and 
long-lasting antidepressant properties. Importantly, GABABR antagonism 
prevents the increase in mTOR activity and thus mTOR dependent protein 
synthesis, as well as the antidepressant behavioral phenotype with rapid 
antidepressants13. Remarkably, ethanol promotes the same shift in GABABR 
function from reducing to increasing dendritic resting calcium levels with GABABR 
activation. Further dissection of this pathway indicates that the Fragile-X mental 
retardation protein may play a role in the initial increase in translation of dendritic 
GABABRs79.  
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Figure 1.3. Model of acute NMDAR inhibition 
 
This model depicts the proposed pathway initiated by NMDAR antagonism 
leading to increased synaptic protein synthesis. Numbers indicate the suspected 
order of events upon inhibition of NMDAR including: initiation of translation of 
new synaptic GABABRs, a switch in function of these new receptors, increased 
intracellular calcium, activation of mTOR and protein translation that may alter 
synaptic plasticity.  
 
Fragile-X mental retardation protein (FMRP) is an RNA-binding protein 
that regulates translation by preventing ribosomal translocation of its target 
mRNA (including the confirmed FMRP targets: GABABR1 and GABABR2)106. 
FMRP is thought to influence synaptic plasticity of specific proteins by regulating 
activity dependent protein synthesis. Neuroadaptations require the translation of 
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pre-existing dendritic mRNA, and FMRP is a key regulator of synaptic mRNA 
translation107. Synaptic changes produced by ethanol exposure may require 
translation of proteins from localized mRNAs93. An investigation comparing 
FMRP targets and differentially expressed genes in the hippocampus of human 
alcoholics identified using RNA-seq data shows a significant overlap. This 
suggests that the differentially expressed genes in human alcoholics may be 
regulated by FMRP. This overlap was observed in the hippocampus, but not in 
other brain regions (Fig. 1.4). Furthermore, GABABRs are known to correlate with 
lifetime consumption of alcohol in humans108, and FMRP was discovered to play 
a role in mediating cocaine induced behavioral and synaptic plasticity109. These 
data indicate that FMRP may be a key regulator of differential protein expression 
in alcohol and other drugs of addiction that may contribute to neuroadaptive 
changes with addiction. It is clear that regulation of protein translation is 
important to drug induced neuroadaptive changes; however, mechanisms that 
induce translation with alcohol remain undiscovered. 
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Figure 1.4. Differentially expressed genes in human AUD overlap with FMRP 
targets 
 
Differentially expressed genes (DEGs) from humans affected by an AUD in the 
prefrontal cortex, nucleus accumbens, and hippocampus (p=0.01) was found to 
significantly overlap only in the hippocampus with known FMRP targets (p=0.05) 
at a p value of 0.008 as determined by Chi2 test with Yates. This implicates the 
hippocampus as an important brain region for altered gene expression and 
possible FMRP regulation.  
 
The Alcohol and Antidepressants Transcriptome  
The effect of alcohol and antidepressants on protein translation and synaptic 
pathways has been discussed; however upstream mRNA transcription is vital to 
the changes seen in protein expression with drug exposure. Gene expression 
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studies provide evidence for alcohol- and antidepressant-induced changes in 
mRNA transcription. A powerful approach to characterizing the transcriptome is 
RNA sequencing.  RNA sequencing is a method that can be used to estimate 
gene and alternative exon expression levels, allowing for identification of novel 
genes and exons110, 111. In this section we will discuss transcriptome studies 
associated with alcohol and antidepressant studies using methods such as RNA 
sequencing.  
Acute Alcohol 
 
Drug induced changes in gene expression are proposed as critical molecular 
adaptations leading to addiction with repeated drug exposure60. RNA-sequencing 
of postmortem human tissue shows consistent differences in transcriptome 
organization linked with lifetime consumption of alcohol112. Particularly, RNA-
sequencing of human hippocampal tissue identified differentially expressed 
genes related to alcohol and addiction60, 113. Chronic drinking in humans and 
animals provide evidence for the association of alcohol-induced changes in 
genes expression114. Human studies often yield complementary results and tend 
to validate animals models of exposure60. Some acute alcohol treatment studies 
in animals have also identified alterations in the transcriptome. Acute ethanol 
exposure for 4 hours alters gene expression in mice, including genes involved in 
neuroplasticity114. Alcohol and other drugs of abuse acutely administered to mice 
identified modules of drug-induced genes that may play a critical role in early 
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stages of addiction115. Current evidence suggests that investigating acute effects 
on brain gene expression could provide insight into mechanisms of reward, as 
well as short- and long-term behaviors associated with addiction116. 
Rapid-Antidepressants 
 
Deficits associated with psychiatric disease including MDD have been found in 
many brain regions including the hippocampus117, and these deficits may be tied 
to consistent changes in gene expression observed across brain regions and 
disorders in individuals with psychiatric disorders117. Specifically in depression, 
transcriptome studies have found altered gene expression in human postmortem 
tissue between control, individuals with MDD, and MDD suicides118. In a 
particular study individuals with MDD were found to have altered expression of 
synapse related genes119, which suggest that synaptic plasticity may play a role 
in depression. To study the acute use of rapid-antidepressants, animal models 
are often used due to the availability of human tissue. Although no previous 
transcriptome sequencing studies have been preformed with the rapid 
antidepressant Ro 25-6981, RAADs that use a similar mechanism such as 
ketamine have been explored in animals. Gene expression following a single 
dose of ketamine was altered in the striatum and hippocampus at acute time 
points95. Patterns of gene expression changes provided novel molecular 
classification of ketamine, and reflect its multi-target pharmacological nature95. 
Analysis of gene regulation of rat hippocampus treated acutely with several 
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antidepressants identified a large array of genes involved in various cellular 
processes suggesting that he therapeutic effect is very complex120. However, 
some RAADs have negative side effects and the potential for abuse making 
alternative drugs for MDD attractive13.  
Alternative splicing 
 
Alternative splicing can generate isoforms that differ in function and 
localization110. Isoforms are important or development, differentiation and 
disease110. Alternative or differential splicing occurs when exons are recombined 
in multiple ways to generate different mRNAs, allowing encoding of multiple 
proteins from a single gene.  These splice events allow for increased biodiversity 
of proteins, regulation of gene expression, and is widespread in mammalian 
genomes. In proteins alternative splicing can be important for altering binding 
properties, localization, enzymatic activity, posttranslational modifications, and 
stability111. Splicing can affect determination of mRNA localization and stability, 
and translation efficiency. Alternative splicing can cause changes in exon 
expression and composition, allowing the production of new protein isoforms 
without observed alterations of original protein expression111. In addition to 
studying differential gene expression we also sought to identify changes in exon 
expression to explore alterations in protein isoforms that were not observable 
with gene expression studies alone.  Many studies have identified alternative 
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splicing in proteins of interest with alcohol or depression118, 121-125, but few have 
identified splicing on a more global, whole genome wide scale.  
Research Rational 
AUD and MDD are both debilitating and widespread disorders with limited 
treatment options. The strong comorbidity between these two disorders suggests 
a connection and warrants further investigation to identify these connections and 
provide an explanation for the overwhelming rate of comorbidity. Understanding 
these disorders may eventually help alleviate the progression to comorbid 
disorders or aid in identification of effective treatment strategies for individuals 
with dual diagnosis. It is well known that AUD and MDD often occur together but 
determining the basis for this requires investigation of co-occurring molecular 
changes with alcohol and antidepressants. This study will provide possible 
molecular changes that cause depressed individuals to self medicate with 
alcohol, and provide the first evidence that acute alcohol can induce an 
antidepressant like behavioral response in mice. The molecular changes we 
have identified may provide targetable avenues for treatment of either or both 
disorders for future study. 
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CHAPTER 2: FMRP REGULATES AN ETHANOL-DEPENDENT SHIFT IN 
GABABR FUNCTION AND EXPRESSION WITH RAPID ANTIDEPRESSANT 
PROPERTIES 
Abstract 
Alcohol promotes lasting neuroadaptive changes that may provide relief from 
depressive symptoms, often referred to as the self-medication hypothesis41. 
However, the molecular/synaptic pathways that are shared by alcohol and 
antidepressants are unknown. In the current study, acute exposure to ethanol 
produced lasting antidepressant and anxiolytic behaviors. To understand the 
functional basis of these behaviors, we examined a molecular pathway that is 
activated by rapid antidepressants. Ethanol, like rapid antidepressants, alters γ-
aminobutyric acid type B receptor (GABABR) expression and signaling, to 
increase dendritic calcium. Furthermore, new GABABRs are synthesized in 
response to ethanol treatment, requiring fragile-X mental retardation protein 
(FMRP). Ethanol-dependent changes in GABABR expression, dendritic signaling, 
and antidepressant efficacy are absent in Fmr1 knockout (KO) mice. These 
findings indicate that FMRP is an important regulator of protein synthesis 
following alcohol exposure, providing a molecular basis for the antidepressant 
efficacy of acute ethanol exposure. 
Introduction 
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The presence of major depression increases the risk of alcohol use disorders 
(AUD) by ~2 fold (and vice versa)14. The self-medication hypothesis suggests 
AUDs may develop when the initial antidepressant actions of alcohol are shifted 
to depressant allostatic states with chronic abuse101. The molecular mechanism 
underlying the initial anti-depressant effects of alcohol is unknown.   
A major advance in understanding and treating depression is the 
recognition that NMDA receptor (NMDAR) antagonists act as rapid and effective 
antidepressant drugs126.  A single injection of an NMDAR antagonist or “rapid 
antidepressant” is effective within 2 hours and has sustained antidepressant 
efficacy for 2 weeks25. These long-lasting properties depend on the activity of 
mammalian target of rapamycin (mTOR)13, 74, a serine/threonine kinase essential 
for mRNA translation98. Recently, we demonstrated that activation of mTOR-
dependent protein synthesis by NMDAR antagonists requires a shift in GABABR 
signaling from opening potassium channels to facilitating an increase in dendritic 
calcium13, 78. Interestingly, both acute ethanol and rapid antidepressants block 
NMDARs25, 52. In light of these data, we propose that ethanol has lasting 
antidepressant efficacy, shares the same downstream molecular signaling events 
as rapid antidepressants, and requires de novo protein synthesis (Supplementary 
Fig. 2.1). 
Studies suggest that antidepressant efficacy requires two phases— an 
induction phase and a sustained phase127, 128. Notably, GABABR-mediated, 
mTORC1-dependent protein synthesis is required for the long-lasting sustained 
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phase of rapid antidepressants. Our previous work indicates that both new 
protein synthesis and an increase in protein stability are required for the GABABR 
shift in function necessary to increase mTORC1 activity78. However, the 
mechanism that initiates such dynamic changes in protein expression by rapid 
antidepressants remains unclear. 
FMRP is an RNA binding protein that has been characterized as a 
repressor of mRNA translation. Some forms of synaptic activity trigger FMRP to 
release its targets, allowing them to be translated129, 130. Moreover, degradation 
and new protein synthesis of FMRP creates a window for the translation of 
specific mRNAs, facilitating long-lasting changes in synaptic function131, 132. 
Complete loss of FMRP results in Fragile X syndrome (FXS), the single most 
common genetic cause of autism87. Moreover, reduced levels of FMRP, caused 
by a pre-mutation, lead to a higher incidence of tremors, ataxia, memory loss, 
and neuronal neuropathy in older men133. These findings argue that precise 
levels of FMRP protein and its target mRNAs are required for normal neuronal 
function. 
Drugs of abuse promote profound changes in gene expression, mRNA 
translation rates, and synaptic protein composition134, 135. Some studies suggest 
that drugs and alcohol highjack the molecular mechanisms that underlie synaptic 
plasticity45, 136. In agreement with this premise, FMRP has been implicated in 
cocaine addiction109. However, little is known about the mRNA targets and the 
signaling mechanisms involved. Here we describe a critical role for FMRP in 
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mediating GABABR synthesis and plasticity following acute ethanol exposure, a 
mechanism required for antidepressant efficacy.  
Methods 
Cell culture   
Primary hippocampal neurons were prepared as previously described by Niere et 
al., 2012137 . Briefly, hippocampi were extracted from postnatal day 1-3 Sprague-
Dawley rat pups, wildtype C57BL/6 mouse pups, or Fmr1-knockout (Fmr1 KO) 
mouse pups on a C57BL/6 background. The tissue was dissociated and plated in 
neurobasal A medium supplemented with B27, glutamine, and 1% fetal bovine 
serum. Cultures were plated at a density of ~100,000 cell/12mm on glass 
coverslips that had been coated overnight with 50 µg/ml poly-D-lysine and 25 
µg/ml laminin in borate buffer. Cultures were fed after 1 day in vitro (DIV), and 
media was replaced approximately once a week with either fresh rat culture 
media (neurobasal A supplemented with B27, glutamine, and 3 µM AraC) or 
fresh mouse culture media (glial-conditioned media with 3 µM AraC) until cultures 
were used at DIV 14-21.  
 
In vitro pharmacology   
Primary hippocampal neurons were treated in ethanol vapor chambers according 
to a method adapted from Chandler et al., 1993138. Ethanol vapor chambers were 
prepared by placing a reservoir of 31.5 mM ethanol (105% of the desired ethanol 
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concentration, i.e., 30 mM) in a plastic container with 24-well culture plates 
containing neuronal cultures in which 30 mM ethanol was added to the culture 
media. Chambers were filled with 95% O2/5% CO2 and cultures were incubated 
for 2 hours at 37oC. Cultures treated with vehicle (H2O) were incubated in the 
same manner but in the absence of ethanol. For calcium imaging ethanol was 
added directly to HEPES-based artificial cerebral spinal fluid (ACSF in mM: 100 
NaCl, 10 HEPES (pH 7.4), 3 KCl, 2 CaCl2, 1 MgCl2, 10 glucose) that was 
adjusted to match the osmolarity of cell culture media for live-imaging. For 
GABABR activation neurons were treated with (R)-baclofen (50 µM, Tocris).  For 
Fig. 2.5 and 2.6, cultured hippocampal neurons were pre-treated for with 
cycloheximide (50 µM, Tocris) for 10 minutes before ethanol treatment. For 
Supplementary Fig. 2.3 neurons were treated with Ro 25-6981 (10 µM, Tocris) or  
Veh (H2O) for 2 hours. All cultures were treated at 14-21 DIV. Following 
treatment, cultures were immediately fixed or live imaged.  
 
In vivo pharmacology    
Male C57BL/6 mice (Charles Rivers) or Fmr1 knockout (Fmr1 KO) mice on a 
C57BL/6 background (at least 7 weeks old) were given intraperitoneal (i.p.) 
injections of either 200 µl saline or 2.5 g kg-1 ethanol (in a volume of 200 µl 
saline)23 . For Fig. 2.8 CGP-35348 (100 mg kg-1) was i.p. injected with or without 
ethanol (in a volume of 200 µl saline). All animals were housed 4 mice per cage 
according to genotype. All treatments were administered to one mouse per home 
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cage. At the time of drug treatment, animals were coded by number. During the 
behavioral tasks, animal performance was video recorded, and then later blindly 
scored. In certain tasks (e.g. open field), the animals were scored by a computer 
program and blinding was not necessary during that process. For Western blots 
the hippocampi were isolated 30 minutes post-injection and flash frozen. All 
experiments were carried out in accordance with the National Institutes of 
Health’s Guide for the Care and Use of Laboratory Animals and approved by the 
UT-Austin Institutional Animal Care and Use Committee (IACUC).   
 
Immunofluorescence   
Primary neuronal cultures on glass coverslips were fixed with 4% 
paraformaldehyde (PFA) at room temperature (RT) for 20 minutes, washed 3 
times with phosphate buffered saline (PBS), and permeabilized in 0.25% Triton 
X-100 in PBS for 5 minutes. For FMRP staining, neurons were fixed and 
permeabilized in 100% methanol at -20oC for 10 minutes. Neurons were washed 
3 times in PBS and then blocked (10% normal goat serum in PBS) for 30 minutes 
at RT. Primary antibodies were incubated in blocking buffer at 4oC overnight. 
Neurons were washed 3 times for 10 minutes with PBS, and then incubated in 
secondary antibody in blocking buffer for 1 hour at RT, and washed 3 times for 
10 minutes with PBS before mounting in Fluoromount with DAPI 
(SouthernBiotech, 0100-20) as outlined in Sosanya et al., 2013139. Surface 
staining was performed similarly to Workman et al., 201313. Neurons were first 
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fixed in 4% PFA for 10 minutes on ice, washed 3 times in PBS, blocked with 3% 
normal goat serum, and then incubated in primary surface antibody in 3% 
blocking buffer overnight at 4oC. Following primary surface antibody incubation, 
neurons were washed 6 times for 10 minutes each in PBS, then permeabilized 
with 0.25% Triton X-100 in PBS for 5 minutes, followed by 3 washes for 10 
minutes each in PBS, and again incubated in primary total antibody in 3% 
blocking buffer overnight at 4oC. Neurons were washed 3 times for 10 minutes 
each with PBS, and then incubated in secondary antibody in 3% blocking buffer 
for 1 hour at RT, and finally washed 4 times for 10 minutes with PBS before 
mounting in Fluoromount with DAPI to slides. The primary antibodies used were: 
Total GABABR1 (1/50 dilution; Santa Cruz, sc-14006), Surface GABABR1 (1/200 
dilution; Abcam, ab55051), GABABR2 (1/100; Neuromab 75-124), FMRP (1/500 
dilution; Abcam ab17722), MAP2 (1/2000 dilution; Abcam ab5392), GFP (1/1,000 
dilution; Aves, GFP-1020). Secondary antibodies included: Alexa488, 555, 
and 647 developed in goat (1/500 dilution; Life Technologies, A-11039, A-11017, 
A-31621, A-21430, A-21449, A-21240, A-21237).   
Adeno-associated viral vectors   
The FMRP and tdTomato coding sequences were cloned into separate adeno-
associated viral (AAV) vectors containing a mouse synapsin promoter, a 
woodchuck post-transcriptional regulatory element (WPRE), and SV40 poly-
adenylation sequence between flanking AAV2 inverted terminal repeats. rAAVs 
were assembled using a modified helper-free system (Stratagene) as serotype 
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2/1 (rep/cap genes) viruses, and  harvested and purified over sequential cesium 
chloride gradients as previously described140. Viral titers were greater than 1x109 
infectious particles per microliter. For FMRP and tdTomato co-infections, 
rAAV:mSYN-FMRP and rAAV:mSYN-tdTomato were mixed at a ratio of 4:1. One 
microliter of the resulting rAAV mix was used per coverslip of primary cultured 
neurons. Imaging was  performed ~1 week after infection.   
Live calcium imaging 
Dissociated hippocampal cultures were prepared from wildtype (WT) and Fmr1 
KO mice as described137. Neurons at 14-21 DIV were used for live calcium 
imaging. Neurons were treated as outlined in in vitro pharmacology above. 
Before imaging, cells were incubated in ACSF with Oregon Green 488 BAPTA-1 
AM (OGB, 200 µM; 30 min; 37°C; ThermoFisher) as described13. After OGB 
incubation, cells were transferred to fresh ACSF (37°C) for imaging (1 frame/20 
s). Baseline calcium signal was imaged (1 min), after which (R)-baclofen (50 µM, 
Tocris) or vehicle (H2O) was added. For ethanol-treated cells, the neurons were 
incubated with OGB and imaged in ACSF containing ethanol (30 mM). Neurons 
were imaged for 800 s at RT.  Quantification of the calcium signal was performed 
using Metamorph (Molecular Devices) as described13. Briefly, dendritic regions of 
interest (ROI) that were at least 5 µm from the soma were analyzed. The mean 
intensity values for each ROI at each time were averaged as baseline (F0). The 
ROI intensity values obtained at each time point after the addition of baclofen or 
vehicle were averaged (F). The equation, ΔF/F = ((F − F0)/F0), was used to 
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measure the change in signal and data were plotted as a percentage of the 
baseline. 
BONCAT-PLA   
BONCAT-PLA was performed using Click-it Metabolic Labeling AHA, Biotin-
Alkyne, and Click-iT Reaction buffer kit (Life Technologies). Proximity ligation 
assay (PLA) was performed using Duolink kit (Duolink, Sigma)141. Briefly, primary 
hippocampal neuronal cultures were incubated in a methionine-free artificial 
cerebral spinal fluid (ACSF) media for 30 minutes. AHA was then added to the 
media just before neurons were treated with ethanol for 2 hours as previously 
described. Neurons were fixed in 4% PFA for 15 minutes, washed 2 times for 5 
minutes with 3% Bovine Serum Albumin (BSA) in PBS, followed by 
permeabilization with 0.25% Triton X-100 in PBS for 15 minutes, and washed as 
before. Neurons were incubated for 30 minutes at RT in Cell Buffer 
Additive/Click-it Cocktail according to manufacturer directions. Neurons were 
washed as before and then blocked and incubated with primary antibody as 
previously described. Next, neurons were incubated in the appropriate PLA 
probes diluted in blocking buffer and secondary antibody at 37oC for 1 hour. 
Neurons were washed in RT Buffer A 2 times for 5 minutes, and incubated in 
ligation solution at 37oC for 30 minutes, and washed again in Buffer A. Neurons 
were incubated in amplification solution at 37oC for 2-3 hours, followed by 
washing in RT Buffer B 2 times for 10 minutes and 1% buffer B for 1 minute. 
Lastly, neurons were mounted to slides in Duolink mounting media for imaging. 
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Primary and secondary antibodies included: GABABR1 (1/50 dilution; Santa 
Cruz, sc-14006), GABABR2 (1/100; Neuromab 75-124), MAP2 (1/2000 dilution; 
Abcam, ab5392), biotin/α-rabbit (1/500; Sigma, SAB3700857), Alexa488 (1/500; 
Life Technologies, A-11039). PLA probes used: Rabbit Minus (1/5; Duolink, 
82005), Mouse Plus (1/5; Duolink, 82001).  
Microscopy and analysis   
Images were acquired with a Leica SP5 confocal microscope under a 63X oil 
immersion lens for fixed tissue or a 63X water immersion lens for live imaging. 
Max projected images were used for immunostaining analysis from 10 µm Z-
stacks of 1024 x 1024 pixels obtained using a 400-Hz scan rate139. For each 
experiment, all images were collected using the same settings. Fixed images 
were analyzed using NIH imaging software ImageJ, and live imaging 
quantification was performed with Metamorph (Molecular Devices, Sunnyvale, 
CA). Background signal was determined by shifting the ROI adjacent to the 
dendrite being traced, but void of all processes. Dendritic signal was background 
subtracted and averaged every 10 µm using a customized R script.   
Western blot analysis   
Protein was isolated from hippocampal synaptoneurosomes (SN) prepared from 
male mice age 7-8 weeks treated with ethanol or vehicle as previously described. 
SNs were prepared by homogenizing hippocampal tissue in homogenization 
buffer (20 mM HEPES pH 7.4, 5 µM EDTA pH 8.0, and protease inhibitor 
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cocktail). Homogenate was filtered through a 100-µm nylon filter followed by a 5-
µm filter, and centrifuged at 14000 x g for 20 minutes at 4oC142. The pellet was 
resuspended in RIPA buffer (150 mM NaCl; 10 mM Tris pH 7.4, 0.1% SDS, 1% 
Triton X-100, 1% deoxycholate, 5 mM EDTA, and protease inhibitor cocktail) and 
centrifuged for 10 minutes. The supernatant was used for Western  blot 
analysis. Protein was separated on a 4-20% gradient SDS-polyacrylamide gel. 
The gel was then transferred to a nitrocellulose membrane, blocked in 5% non-
fat dry milk in tris-buffered saline and 0.1% tween20 (TBST) for 1 hour, and 
incubated with primary antibody in blocking buffer overnight at 4oC. The blot was 
washed in TBST 3 times for 10 minutes each, incubated in secondary antibody 
for 1 hour, and washed as before. Blots were imaged using a LICOR Odyssey 
imaging system, and ImageJ was used for densitometry analysis. Representative 
images are pseudocolored with black (lowest intensity at 0 pixels) to red (highest 
intensity at 255 pixels) using LICOR Image Studio software. Primary antibodies 
used consisted of: GABABR1 (1/400 dilution; Santa Cruz, sc-14006), GABABR2 
(1/800; Neuromab 75-124), alpha-Tubulin (1/2000 dilution; Sigma, T6074). 
Secondary antibodies included: anti-mouse-IR-Dye 800 (1/5000 dilution 
excluding tubulin at 1/10,000 dilution; LICOR, 96-32210) and anti-rabbit 
Alexa680 (1/5000 dilution; Invitrogen, A-21084).   
RNA Immunoprecipitations 
Cortices from 6-week old C57BL/6 and Fmr1 KO male mice were harvested and 
flash frozen on dry ice. RIP was performed by modified method of Jain et al., 
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2011 and Keene et al., 2006143, 144.  Tissue was homogenized and lysed with a 
cordless pestle motor and disposable pellet mixers (VWR) in polysome lysis 
buffer (10 mM HEPES pH 7.0, 100 mM KCl, 25 mM EDTA, 5 mM MgCl2, 1mM 
DTT, 0.5% NP-40) in a 1:1 tissue-buffer ratio. RNaseOUT (Thermo) and 
protease/phosphatase inhibitors (Halt™ Protease and Phosphatase Cocktail, 
Pierce Biotechnology) were freshly added to samples. Samples were rotated for 
10 minutes at 4°C to induce swelling and then flash frozen on dry ice. Samples 
were thawed by holding between fingers at RT to lyse and nuclei were pelleted at 
3000 x g for 10 minutes. Lysates obtained above were pre-cleared by adding 50 
µl of washed magnetic bead slurry (Protein A Dynabeads, Thermo) and rotating 
for 30 minutes at 4°C. To bind the antibody to the beads, 50 µl of magnetic beads 
slurry was washed and then resuspended in 8 volumes of NT-2 buffer (50 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1mM DTT, 0.05% NP-40 with 
RNaseOUT/protease & phosphatase inhibitors added fresh) + 5% BSA. 10 µg of 
either FMRP (Abcam, ab17722) or IgG (Santa Cruz Biotechnologies, sc-2027) 
antibodies were added to the beads and rotated for 10 minutes at RT. Antibody-
bound beads were washed 4 times with ice-cold NT-2 buffer. For the 
immunoprecipitation, 4.5 mg of protein from pre-cleared lysates was added to an 
RNase-free microcentrifuge tube containing the antibody-bound beads. Input 
collected at this step for downstream analysis was either 1% of the final pre-
cleared lysate volume in the immunoprecipitation reaction (for immunoblotting) or 
10% of the final pre-cleared lysate volume (to normalize in qPCR). The antibody-
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bead-lysate mixture was then diluted at a ratio of 1:5 with NET-2 buffer (20 mM 
EDTA pH 8.0, and 1 mM DTT in NT-2 buffer; RNaseOUT and 
protease/phosphatase inhibitors added fresh) and rotated for 1 hour at room 
temperature. Beads were quickly washed 6 times in ice-cold NT-2 buffer and 
immediately resuspended in 350 µl TRI Reagent® Solution (Ambion) for 10 
minutes at RT. Beads were pelleted and the supernatant was removed and 
resuspended in 350 µl of absolute ethanol. RNA was extracted by applying 
ethanol-resuspended samples to spin column from the Direct-zol RNA MiniPrep 
Kit (Zymogen) according to manufacturer’s instructions. Eluted RNA (25 µl) was 
DNase treated using the TURBO DNA-free kit (Thermo).  
cDNA Synthesis and Quantitative Real-Time PCR (qRT-PCR) 
DNase-treated RNA samples were reverse-transcribed to cDNA using the iScript 
cDNA Synthesis Kit (Bio-Rad) in a 20 µl volume according to manufacturer’s 
instructions. qRT-PCR was performed in 20 µl reaction volume using the iQ™ 
SYBR® Green Supermix (Bio-Rad) and primers for GABABR1, GABABR2, 
CaMKIIα, and Cacna2δ2 (GeneCopoeia). qRT-PCR was run with the following 
protocol: 95°C for 10:00, 40 cycles of 95°C for 0:15 followed by 60°C for 1:00, 
95°C for 1:00, and 55°C for 1:00. Relative fold-enrichment was determined by the 
equation ΔΔCt = 2-(Ct FMRP RIP – Ct IgG RIP) - (Ct FMRP input – Ct IgG input) 145. 
Forced Swim Test 
Male mice were tested in the forced swim test 24 hours post-injection as 
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described previously13, 78. Mice were individually placed into a cylinder containing 
3 L of water (25°C) for 6 minutes. Each session was video recorded and the last 
4 minutes of the sessions were later scored blindly for immobility. Animals were 
scored for escape-directed behaviors. The water was replaced between animals. 
Experiments were repeated by 3 independent experimenters. Data was 
normalized by experimenter. Power analysis was performed in R Programming146 
to predict sample size for all behavioral tests. This sample size was used as a 
guideline for the wild type animals, however since transgenic animals were used, 
the exact sample size for each group may not have been possible. Transgenic 
animal sample size was as close as possible to that which was calculated, due to 
limitations of litter size. 
Open Field 
Twenty-four hours after animals were injected i.p. with either saline or ethanol, 
they were studied in the open field test similar to Treit et al, 1988147. Mice were 
individually placed in a 40 cm x 40 cm x 35 cm arena with opaque walls. Each 
test session lasted 30 minutes under 85 lux illumination. Sessions were video 
recorded and analyzed via ANY-Maze (Stoelting, Wood Dale, IL). Mice were 
considered to be in the center of the maze if they entered a 18.5 cm x 18.5 cm 
area in the center of the apparatus. Mice were returned to their home cage at the 
end of the test session, and the arena was wiped down with 70% ethanol before 
the start of each run.  
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Splash Test 
Two and a half hours after open field testing, animals underwent the splash 
test148, 149. Cage mates were moved from their home cage to a holding cage, and 
each animal was individually tested in its home cage. Two hundred microliters of 
10% sucrose was applied to the dorsal fur of the mouse. Mice were monitored 
and video recorded for 5 minutes and then moved to a different holding cage. 
Videos were later scored blindly for latency to initiate grooming and for total time 
spent grooming. Grooming behavior included licking, grooming with forepaws, 
and scratching.  
Statistical analysis   
Power analysis was performed in R Programming146 to predict sample size. 
Prism software (GraphPad) was used for all statistical analyses. Statistical 
comparisons were made using one-way ANOVA, two-way ANOVA, Student’s t-
test, or Chi2 test with Yates. Outliers were determined using Grubbs’ test 
(alpha=0.05). All data are expressed as mean ± Standard Error of the Mean 
(SEM). 
Results 
Antidepressant and anxiolytic effects of ethanol on behavior  
 
To determine if acute alcohol has antidepressant properties, as predicted by the 
self-medication hypothesis, we first assessed the efficacy of alcohol on 
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antidepressant- and anxiolytic-like effects on behavior. The forced swim test 
(FST) is a rodent behavioral test predictive of antidepressant activity in 
humans150. Rodents treated with a single injection of NMDAR antagonists or 
rapid antidepressants swim longer and thus have reduced immobility relative to 
controls. Notably, these positive effects on behavior last long after the drug has 
been metabolized13, 70, 74, 78. Therefore, we considered the possibility that ethanol, 
which blocks NMDARs52, could also act like an antidepressant at 24 hours, well 
beyond the intoxication period151. To test this, C57BL/6 mice were injected with 
ethanol (2.5 g kg-1, intraperitoneal (i.p.)), a concentration that is achieved during 
self-administration in mice152. Twenty-four hours after injection, the immobility of 
ethanol-treated mice was reduced by ~15% relative to controls (Fig. 2.1a), similar 
to our previous observation in mice that had been exposed to the rapid 
antidepressant Ro 25-698113, 78. These results demonstrate that acute ethanol 
elicits a lasting antidepressant effect on behavior similar to that seen with rapid 
antidepressants78. 
 As another measure of antidepressant effect of ethanol on behavior, we 
assessed the grooming behavior of mice using the splash test after ethanol or 
saline administration. The splash test measures latency to groom and dedicated 
grooming time as indicators of self-care and motivational behavior148, 149. Lack of 
self-care is often observed in humans with depressive disorder12. We have 
previously shown that mice receiving a single i.p. injection of the rapid 
antidepressant Ro 25-6981 spend more time grooming compared to control 
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mice78. We hypothesized that ethanol would produce similar effects on grooming 
behavior. Indeed, ethanol-treated mice spent more time grooming and displayed 
shorter latency to initiate grooming relative to controls (Fig. 2.1b and c).  
 Ethanol is a well-known anxiolytic substance67. However, the anxiolytic effect 
of a single dose of ethanol 24 hours after administration has not been 
determined. We subjected ethanol- and saline-injected mice to the open-field test 
to assess the influence of ethanol on anxiety-like behaviors after 24 hours. Mice 
that spend more time in the center of the open field are scored as having 
reduced anxiety-like behavior relative to mice that remain close to the 
perimeter147. Indeed, mice that received a single dose of ethanol (2.5 g kg-1, i.p.) 
had reduced anxiety-like behavior, spending ~40% more time in the center 
relative to controls (Fig. 2.1d). There was no significant difference in total 
distance traveled or average speed between the groups (Fig. 2.1e-f). These data 
suggest that the anxiolytic effects of ethanol last up to 24 hours post-injection.  
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Figure 2.1. Ethanol elicits a lasting antidepressant-like effect on behavior 
 
(a) C57BL/6 male mice were subjected to the forced swim test 24 hours after i.p. 
injection with vehicle (Veh; saline) or ethanol (ETOH; 2.5g kg-1). Ethanol 
treatment reduced immobility, indicating antidepressant efficacy. Veh=100 ± 2.5, 
n=10 mice; ETOH=86 ± 7.4, n=6. (b-c) In the splash test, male C57BL/6 mice 
groomed longer and took less time to initiate grooming 24 hours post-ethanol 
(2.5 g kg-1, i.p.) compared to 24 hours post-vehicle (saline, i.p.) treatment. Total 
groom time: Veh=11.34 ± 4.23 s, n=6; ETOH=35.37 ± 6.72 s, n=5. Latency to 
groom: Veh=225.2 ± 34.13 s, n=6; ETOH=77.55 ± 28.44 s, n=5. (d-f) Total center 
time, speed, and distance were measured in the open field test 24 hours post-
injection. Ethanol-treated (2.5 g kg-1, i.p.) mice spent more time in the center, 
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while speed and distance were unaffected compared to vehicle-treated (saline, 
i.p.) mice, indicating an ethanol-induced anxiolytic effect without altering mobility. 
Total center time: Veh=327.5 ± 35.62 s, n=6; ETOH=459.2 ± 19.13 s, n=6. 
Average speed: Veh=0.042 ± 0.002 m/s, n=6; ETOH=0.041 ± 0.002 m/s, n=6. 
Total distance: Veh=75.35 ± 3.92 m, n=6; ETOH=73.00 ± 3.35 m, n=6. 
Significance determined by one-tailed t-test. Values represent mean ± SEM. 
 
Acute ethanol increases GABABR2 and surface GABABRs  
 
Both ethanol and rapid antidepressants block NMDARs in the hippocampus25, 52. 
One of the first events triggered by NMDAR antagonism is increased dendritic 
GABABR2 protein expression78. GABABRs are obligate heteromultimers, 
consisting of GABABR1 and R2. GABABR2 is required for expression of receptors 
at the surface by masking an endoplasmic reticulum retention sequence on 
GABABR1153. Similarly, treatment with a rapid antidepressant leads to (1) 
increased dendritic expression of GABABR2 but not GABABR178, and (2) a 
corresponding increase in surface expression of GABABR113, 78.  
To determine if acute ethanol exposure in vivo rapidly increases the levels 
of GABABR1 and/or GABABR2, hippocampal synaptoneurosomes were isolated 
from mice that had been injected with a single dose of ethanol (2.5 g kg-1, i.p.) or 
saline for Western blot analysis. The hippocampi were collected within the 
initiation phase (30 minutes post-injection), a phase where molecular changes 
facilitate increased downstream mTORC1 activity128. Consistent with rapid 
antidepressants, acute ethanol injection increased the protein expression of 
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GABABR2 by ~37% in the hippocampus with no significant change in GABABR1 
(Fig. 2.2a-c; uncropped blots, Supplementary Fig. 2.7a).   
To further identify the subcellular localization of ethanol-induced increase 
in GABABR2, we examined GABABR expression in cultured hippocampal 
neurons.  GABABR1 and R2 were immunostained and quantified in the dendrites. 
A concentration of 30 mM ethanol was chosen, as it has been shown to reduce 
NMDAR activity in hippocampal neurons and reflects that achieved in vivo 
following i.p. injection52, 154. Acute ethanol exposure (30 mM, 2 hours) increased 
the dendritic levels of GABABR2 by ~47%, but did not affect GABABR1 levels 
(Fig. 2.2d-g). We did not observe a difference in the diameter of the primary 
dendrites between vehicle- and ethanol-treated neurons, demonstrating that 
ethanol does not modify dendritic caliber (Supplementary Fig. 2.2). These in vivo 
and in vitro findings establish a role for ethanol in increasing GABABR2 protein 
expression.  
Since GABABR2 is required for the surface expression of the 
heteromultimeric receptor, we predicted that the ethanol-induced elevation in 
GABABR2 levels would increase expression of receptors at the surface. We 
measured the surface expression of dendritic GABABRs using an antibody 
directed against the extracellular domain of GABABR1 in unpermeabilized 
hippocampal neurons. The surface signal was normalized by the total dendritic 
GABABR1 levels after permeabilization13. As predicted, surface expression of 
GABABRs in ethanol-treated neurons was significantly higher (~66% increase) 
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relative to controls (Fig. 2.2h-i). This ethanol effect was consistent with what we 
previously observed following rapid antidepressant treatment of cultured 
hippocampal neurons13. Collectively, these results suggest that ethanol promotes 
the surface expression of GABABRs, and this is likely achieved by increasing 
GABABR2 protein levels13, 78, 153. 
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Figure 2.2. Acute ethanol increases dendritic GABABRs in hippocampus 
 
(a-c) Western blot analyses of GABABR1 and GABABR2 in isolated hippocampal 
synaptoneurosomes from ethanol-treated (ETOH; 2.5g kg-1 i.p.), and vehicle-
treated (Veh; saline i.p.) C57BL/6 male mice 30 minutes post-injection. (a) 
Pseudocolored representative Western blots to show intensity with normalized 
optical density for each band indicated below blot (Lookup table, below Western 
blot). No significant change was observed in (b) GABABR1, but a significant 
increase was found in (c) GABABR2 with ethanol treatment. Western blots were 
normalized to the loading control, α-Tubulin. GABABR1: Veh=1.00 ± 0.11; 
ETOH=1.19 ± 0.08. Experiment was repeated 5 times. GABABR2: Veh=1.00 ± 
0.07; ETOH=1.37 ± 0.05. (d-e) Representative immunostaining images of 
GABABR1 and GABABR2 in cultured rat hippocampal dendrites normalized to 
microtubule associated protein 2 (MAP2) as volume control. There was no 
change in (f) GABABR1 and a significant increase in (g) GABABR2 in ethanol-
treated (30 mM, 2 hours) compared to vehicle-treated (H2O, 2 hours) dendrites: 
Total GABABR1: Veh=1.00 ± 0.03, n=46 dendrites; ETOH=1.04 ± 0.04, n=51 
dendrites. Total GABABR2: Veh= 1.00 ± 0.03, n=46 dendrites; ETOH=1.47 ± 
0.05, n=51 dendrites. (h-i) Immunofluorescence shows a significant increase in 
surface GABABR1 expression in dendrites of cultured rat hippocampal neurons 
treated with ethanol (30 mM, 2 hours); (i) Surface expression of GABABR1 in 
vehicle-treated (H2O, 2 hours) and ethanol-treated (30 mM, 2 hours) dendrites. 
Veh=1.00 ± 0.09, n=43 dendrites; ETOH=1.66 ± 0.12, n=47 dendrites. 
Significance determined by Student's t-test. Values represent mean ± SEM. 
Scale bars=5 µm. Uncropped version of western blots, with size markers are 
available in Supplementary Figure 7a. 
 
FMRP regulates the protein expression of GABABR1 and GABABR2 
 
Next we sought to identify the mechanism by which NMDAR antagonism 
increases GABABR2 expression. GABABR2 mRNA is present in the dendrites of 
hippocampal neurons92, suggesting that this mRNA may be locally regulated at 
the translational level. Thus, we examined RNA-binding factors that may regulate 
GABABR2 mRNA expression in dendrites. Notably, both GABABR1 and 
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GABABR2 mRNAs are reported targets of FMRP, an RNA binding protein that 
stalls translational elongation of its targets106, 155.  
To test the hypothesis that FMRP regulates GABABR mRNA translation, 
we first verified that (1) GABABR mRNAs bind to FMRP, and that (2) the absence 
of FMRP in knockout mice results in aberrant expression of GABABRs. Using a 
specific antibody against FMRP, bound mRNAs were isolated using RNA 
immunoprecipitation (RIP). GABABR1 and GABABR2 binding were assessed by 
reverse transcription (RT) and quantitative PCR. Indeed, GABABR1 and 
GABABR2 mRNAs were detected in the immunoprecipitate, along with CaMKIIα, 
a well-known FMRP mRNA target (Fig. 2.3a-b; uncropped representative qPCR 
gels, Supplementary Fig. 2.7d). The calcium channel accessory subunit 
Cacnα2δ2 mRNA is not a reported target for FMRP106 and was used as a 
negative control. Cacnα2δ2 mRNA was not detected in the FMRP RIP (Fig. 
2.3b). In parallel, we used lysates isolated from brains of mice with a genetic 
deletion of the Fmr1 gene. We did not observe amplification of any of the mRNAs 
in Fmr1 KO brains, providing additional evidence for specific binding of FMRP to 
GABABR1 and GABABR2 mRNAs (Fig. 2.3a-c; uncropped blots, Supplementary 
Fig. 2.7b). 
Next, we determined if FMRP regulates GABABR1 and GABABR2 protein 
levels. Genetic deletion of Fmr1 leads to the constitutive translation of FMRP 
target mRNAs and the loss of activity-dependent translation87. Protein levels of 
GABABR1 and GABABR2 were compared in hippocampal synaptoneurosomes 
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from Fmr1 KO and wildtype (WT) mice (Fig. 2.3c-g). GABABR2 basal protein 
levels were elevated by ~53% in Fmr1 KO hippocampi (Fig. 2.3g). GABABR1 
protein levels also increased, albeit to a lesser extent than GABABR2 (Fig. 2.3f). 
Collectively, these data suggest that FMRP regulates the expression of 
GABABR1 and GABABR2. 
 52 
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Figure 2.3. GABABR1 and GABABR2 mRNAs are FMRP targets 
 
(a-b) RNA immunoprecipitation (RIP) for FMRP was performed using brains from 
wildtype (WT) and Fmr1 KO male mice. (a) Gels showing RT-qPCR amplified 
product of input sample, FMRP RIP, and IgG control for GABABR1 and 
GABABR2. (b) Relative fold-enrichment as determined by real-time qPCR relative 
to input control (ΔΔCt = 2-(Ct FMRP RIP – Ct IgG RIP) - (Ct FMRP input – Ct IgG input)). FMRP binds 
GABABR1, GABABR2, and the positive control CaMKIIα mRNA as detected in the 
RIP sample by real-time qPCR. Cacnα2δ2 served as a negative control and was 
not detected above background. WT: GABABR1=2.66 ± 0.248, n=2; 
GABABR2=2.19 ± 0.08, n=2; CaMKII=3.72 ± 0.94, n=2; Cacnα2δ2=0.11 ± 0.6, 
n=2. Fmr1 KO: GABABR1=0.01 ± 0.0002, n=2; GABABR2=0.02 ± 0.00006, n=2; 
CaMKII ± 0.04±0.01, n=2; Cacnα2δ2=0.012 ± 0.005, n=2. (c-g) Western blot 
analysis of hippocampal synaptoneurosomes isolated from C57BL/6 WT and 
Fmr1 KO mice on a C57BL/6 background indicates the absence of (e) FMRP and 
increased protein expression of (f) GABABR1 and (g) GABABR2. Representative 
Western blots are pseudocolored to indicate intensity of bands, and the 
normalized optical density for each band is indicated below blot (Lookup table, 
below Western blot). Western blots were normalized to the loading control, α-
Tubulin. WT: FMRP=1.00 ± 0.10; GABABR1=1.00 ± 0.06; GABABR2=1.00 ± 0.08. 
Fmr1 KO: FMRP=0.03 ± 0.01; GABABR1=1.27 ± 0.08; GABABR2=1.54 ± 0.17. 
Experiment was repeated 3 times. Significance determined by Student's t-test. 
Values represent mean ± SEM. Uncropped versions of qPCR gel, with size 
markers, are available in Supplementary Figure 7d. Uncropped version of 
western blots, with size markers are available in Supplementary Figure 7b. 
 
 
Ethanol and rapid antidepressants reduce dendritic FMRP 
 
As an initial test to determine if FMRP-regulated translation is linked to alcohol 
exposure, we compared FMRP target mRNAs106 with mRNAs that are 
differentially expressed in the hippocampi of alcohol-dependent humans60. 
Remarkably, 225 or ~25% of verified FMRP target mRNAs overlap with mRNAs 
that are altered in alcohol-dependent individuals, suggesting a role for FMRP in 
aberrant protein levels observed in humans with AUD (Fig. 2.4a)60, 106. We then 
determined if exposure to acute ethanol (30 mM, 2 hours) or Ro 25-6981 (10 µM, 
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2 hours) alters FMRP expression in the dendrites of hippocampal neurons. Using 
immunofluorescence, we found that ethanol and Ro 25-6981 reduced FMRP 
levels by ~38% and 45%, respectively (ethanol: Figure 2.4b-c; Ro-25-6981: 
Supplementary Fig. 2.3). These data suggest that ethanol and Ro 25-6981 alter 
protein expression in an FMRP-dependent manner. 
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Figure 2.4. FMRP and AUD share target mRNAs and ethanol decreases FMRP 
 
(a) Venn diagram illustrating the significant overlap between FMRP mRNA 
targets and differentially expressed genes in the hippocampus of humans with 
AUDs. Significance determined with Chi2 test. (b-c) Immunofluorescence images 
normalized to MAP2 as volume control and quantification summary shows a 
significant decrease in FMRP expression in dendrites of cultured hippocampal 
neurons treated with ethanol (ETOH; 30 mM, 2 hours) compared to vehicle-
treated (Veh; H2O, 2 hours). Veh: FMRP =1.00 ± 0.06, n=32 dendrites; ETOH: 
FMRP =0.62 ± 0.03, n=31 dendrites. Significance determined by Student's t-test. 
Values represent mean ± SEM. Scale bars=5 µm. 
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Ethanol-induced synthesis of GABABR2 requires FMRP 
 
Due to the ethanol-induced decreases in FMRP, we hypothesized that FMRP is 
required for ethanol-induced expression of GABABRs. Specifically, if expression 
of GABABRs is constitutive and unregulated in Fmr1 KO mice, then ethanol-
induced changes in GABABR expression should be absent in Fmr1 KO mice. 
Hippocampal synaptoneurosomes were isolated from WT and Fmr1 KO mice 30 
minutes after i.p. injection of ethanol (2.5g kg-1). Western blot analysis indicated 
that both GABABR1 and GABABR2 expression remained constant in vehicle- and 
ethanol- treated Fmr1 KO mice.  As observed in Fig. 2.2, WT hippocampal 
synaptoneurosomes showed an ~23% increase in GABABR2 but no change in 
GABABR1 expression (Fig. 2.5a-c; uncropped blots, Supplementary Fig. 2.7c). 
These data suggest that ethanol-induced changes in GABABR expression are 
dependent on FMRP translational regulation. 
To determine whether protein synthesis is essential for the FMRP-
dependent changes in GABABR expression, we measured ethanol-induced 
GABABRs in the presence of cycloheximide (CHX), a protein synthesis inhibitor. 
As demonstrated previously, ethanol did not influence the dendritic expression of 
GABABR1; however, co-treatment with cycloheximide increased GABABR1 
expression by ~22%. FMRP deletion did not affect the basal, ethanol-, or 
cycloheximide-induced dendritic protein expression of GABABR1 (Fig. 2.5d-e and 
h). For GABABR2, we again saw a significant ~28% increase in dendritic 
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expression with acute ethanol treatment; however, in the presence of 
cycloheximide the ethanol-induced increase was abolished.  Notably in Fmr1 KO 
cultures, no change was observed with ethanol or ethanol+cycloheximide (Fig. 
2.5f-g and i). 
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Figure 2.5. Fmr1 KO prevents ethanol-induced altered GABABR expression 
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a-c) Western blot analysis of GABABR1 and GABABR2 in wildtype (WT) and 
Fmr1 KO C57BL/6 hippocampal synaptoneurosomes after vehicle (Veh; saline 
i.p., 30 minutes) or ethanol (ETOH; 2.5 g kg-1 i.p., 30 minutes) treatment. (a) 
Pseudocolored representative Western blots showing band intensity, and 
normalized optical densities to WT-vehicle are reported below each image 
(Lookup table, below Western blot). Western blots were normalized to the 
loading control, α-Tubulin. No change was found in (b) GABABR1 after ethanol 
treatment in either genotype as shown by ethanol/vehicle comparison. A 
significant increase in (c) GABABR2 expression was observed in WT mice after 
ethanol, but no change was observed in Fmr1 KO mice (shown as 
ethanol/vehicle). WT ETOH/Veh: GABABR1=1.15 ± 0.21; GABABR2=1.22 ± 0.01. 
Fmr1 KO ETOH/Veh: GABABR1=0.94 ± 0.04; GABABR2=0.95 ± 0.03. 
Experiment was repeated 3 times. Significance determined by Student's t- test. 
Values represent mean ± SEM. Representative immunofluorescent images (d-g) 
and quantification summaries (h-i) of dendritic expression of GABABR1 and 
GABABR2 from WT and Fmr1 KO primary mouse hippocampal cultures 
normalized to MAP2. (h) GABABR1 expression was not changed in either 
genotype after 2-hour treatment with vehicle (Veh; H2O), ethanol (ETOH; 30 
mM), or ethanol and cycloheximide (30 mM ETOH+ 50 µM CHX). WT GABABR1: 
Veh=1.00 ± 0.04, n=44 dendrites; ETOH=1.07 ± 0.04, n=29 dendrites; 
ETOH+CHX=1.22 ± 0.05, n=34 dendrites. Fmr1 KO GABABR1: Veh=1.09 ± 0.03, 
n=72 dendrites; ETOH=1.12 ± 0.03, n=41 dendrites; ETOH+CHX=1.42 ± 0.07, 
n=43 dendrites. (i) GABABR2 expression in WT neurons increased after ethanol 
(ETOH; 30 mM, 2 hours) compared to vehicle (Veh; H2O, 2 hours) treatment, and 
was rescued with co-treatment of cycloheximide (CHX; 50 µM, 2 hours). 
GABABR2 expression in Fmr1 KO dendrites was not significantly altered between 
neurons treated with Veh, ETOH, or ETOH+CHX. WT GABABR2: Veh=1.00 ± 
0.03, n=41 dendrites; ETOH=1.28 ± 0.06, n=40 dendrites; ETOH+CHX=0.99 ± 
0.05, n=33 dendrites. Fmr1 KO GABABR2: Veh=1.46 ± 0.05, n=73 dendrites; 
ETOH=1.56 ± 0.04, n=45 dendrites; ETOH+CHX=1.63 ± 0.07, n=36 dendrites. 
Significance determined by two-way ANOVA with Tukey’s post-test. Value 
represent mean ± SEM. Scale bars=5 µm. Uncropped version of western blots, 
with size markers are available in Supplementary Figure 7c. 
 
 
 
We next examined the requirement for protein synthesis and FMRP in 
ethanol-dependent surface expression of GABABRs. Using WT and Fmr1 KO 
hippocampal neurons, we measured ethanol-induced surface expression of 
GABABR1 with or without cycloheximide. Co-assembly of GABABR1 and R2 is 
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required to express GABABR heterodimers in the membrane153. Thus, we 
predicted that the ethanol-induced increase in surface GABABRs would require 
FMRP-regulated synthesis of GABABR2. Again, acute ethanol increased 
dendritic surface GABABRs by ~76%, and this was blocked by cycloheximide. In 
Fmr1 KO neurons there was no significant ethanol-induced change in surface 
GABABRs, but a decrease was observed with ethanol+cycloheximide (Fig. 2.6a-
c). These data suggest that GABABR2 protein synthesis is required for the 
increased surface expression of the hetermultimeric receptor with ethanol 
exposure. 
FMRP is reported to repress new protein synthesis. Considering the 
effects of the protein synthesis inhibitor, these data suggests that the ethanol-
mediated reduction in FMRP results in the increase in dendritic GABABR2 by de 
novo protein synthesis. To provide more direct evidence, we performed 
bioorthogonal noncanonical amino acid tagging (BONCAT) in conjunction with 
proximity ligation assay (PLA-Duolink)141. BONCAT+PLA can be used to detect 
new synthesis of proteins of interest, such as GABABR1 and GABABR2. Through 
click chemistry, noncanonical amino acids that are incorporated during mRNA 
translation are biotinylated. PLA, on the other hand, generates a fluorescent 
signal when two antibodies are within 30-40 nm of each other (i.e., anti-
GABABR1 or GABABR2 and anti-biotin). By combining these methods, we 
determined that ethanol treatment increases new protein synthesis of GABABR2 
by ~40%, but does not alter GABABR1 synthesis, similar to the GABABR changes 
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induced by rapid antidepressants78. In Fmr1 KO dendrites, basal levels of 
GABABR2s increased by ~48%, while a significant decrease was observed in 
GABABR1 levels. Additionally, ethanol-induced translation of GABABR2 was lost 
in Fmr1 KO dendrites (Fig. 2.6d-i). These data provide additional evidence that 
the ethanol-induced increase in GABABR2 expression is due to new protein 
synthesis that requires the release of translational repression by FMRP.  
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Figure 2.6. New GABABR2 protein and surface expression requires FMRP  
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Immunofluorescent images and quantification summary of GABABR1 surface 
expression in wildtype (WT) and Fmr1 KO primary hippocampal cultures 
normalized to MAP2 as volume control. (a-b) Representative images of 
immunostaining. (c) Increased expression of surface GABABR1 in WT dendrites 
after ethanol (ETOH: 30 mM, 2 hours) compared to vehicle (Veh: H2O, 2 hours) 
or ethanol-cycloheximide (30 mM ETOH+ 50 µM CHX, 2 hours) treatment. No 
significant change in surface GABABR1 expression in Fmr1 KO cultures treated 
with ETOH or ETOH+CHX was observed. WT Surface GABABR1: Veh=1.00 ± 
0.08, n=28 dendrites; ETOH=1.76 ± 0.17, n=37 dendrites; ETOH+CHX=1.22 ± 
0.1, n=36 dendrites. Fmr1 KO Surface GABABR1: Veh=1.36 ± 0.13, n=39 
dendrites; ETOH=1.44 ± 0.15, n=42 dendrites; ETOH+CHX=0.91 ± 0.09, n=29 
dendrites. (d-i) BONCAT combined with PLA, a method to detect newly 
synthesized proteins. (d-g) Representative images for GABABR1 and GABABR2 
expression. Pixels were equally dilated by 1 using ImageJ software for enhanced 
visualization as described by Cajigas et al., (2012)92. In WT and Fmr1 KO 
primary hippocampal cultures (h) GABABR1 synthesis in dendrites was not 
altered by ethanol (30 mM, 2 hours) compared to vehicle (H2O, 2 hours) 
treatment normalized to MAP2. WT GABABR1: Veh=1.00±0.09, n=47 dendrites; 
ETOH=0.82±0.08, n=39 dendrites. Fmr1 KO GABABR1: Veh=0.64±0.09, n=38 
dendrites; ETOH=0.48±0.05, n=36 dendrites. (i) In contrast, ethanol induced a 
significant increase in new GABABR2 synthesis in WT hippocampal dendrites but 
not in Fmr1 KO dendrites. WT GABABR2: Veh=1.00 ± 0.06, n=21 dendrites; 
ETOH=1.39 ± 0.11, n=25 dendrites. Fmr1 KO GABABR2: Veh=1.48 ± 0.10, n=32 
dendrites; ETOH=1.23 ± 0.07, n=41 dendrites. Significance determined by two-
way ANOVA with Tukey’s post-test. Values represent mean ± SEM. Scale 
bars=5 µm. 
 
Ethanol-induced GABABR plasticity requires FMRP 
 
We previously demonstrated that rapid antidepressants shift GABABR signaling 
from opening potassium channels to increasing dendritic calcium13. To determine 
if ethanol (30 mM, 2 hours) causes the same plasticity in GABABR signaling, we 
performed fluorescence calcium imaging in cultured WT and Fmr1 KO 
hippocampal neurons. A transient rise or fall in calcium in dendritic compartments 
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can be detected using a fluorescent indicator that exhibits changes in fluorescent 
properties depending on the amount of bound calcium156. We used baclofen, a 
GABABR agonist, to activate GABABRs in the presence or absence of ethanol.  
After establishing a baseline measurement, baclofen reduced dendritic calcium 
fluorescence in saline-treated WT neurons by ~11%, a characteristic signature of 
GABABR signaling increasing outward potassium conductance78. However, in 
ethanol-treated WT neurons, baclofen induced distinct calcium waves and an 
overall averaged increase in calcium signal of ~9% (Fig. 2.7a-c and 
Supplementary Fig. 2.4a and c). These results recapitulate our previous 
observations with NMDAR antagonists13. In addition, these findings in WT mouse 
neurons are consistent with what we observed in rat cultured hippocampal 
neurons treated with ethanol or the clinically relevant rapid antidepressant Ro 25-
6981 (Supplementary Fig. 2.5). Unexpectedly, GABABR activation in saline-
treated Fmr1 KO neurons failed to reduce the calcium signal. Moreover, in 
ethanol-treated Fmr1 KO neurons, GABABR activation failed to increase dendritic 
calcium signal (Fig. 2.7 b-c and Supplementary Fig. 2.4b and c). These findings 
suggest that the loss of FMRP in Fmr1 KO dendrites decouples GABABRs from 
potassium channels. These results also suggest that the dynamic, ethanol-
induced plasticity in GABABR signaling, which is observed with rapid 
antidepressants, requires FMRP13.  
To further substantiate that FMRP regulates ethanol-dependent GABABR 
plasticity, we overexpressed FMRP in rat hippocampal neurons. Overexpression 
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of FMRP did not alter the GABABR activation in saline-treated neurons because 
baclofen reduced the dendritic calcium signal. However, in ethanol-treated 
neurons, overexpressing FMRP blocked the ethanol-induced GABABR plasticity 
(Fig. 2.7d and Supplementary Fig. 2.4d-e). These results provide additional 
evidence that the dynamic reduction of FMRP with ethanol exposure is important 
for the expression of GABABR plasticity.  
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Figure 2.7.  GABABR plasticity and signaling is absent in Fmr1 KO mice 
 
(a-c) Mouse hippocampal cultured neurons were pre-treated for 2 hours with 
either vehicle (Veh: H2O) or ethanol (ETOH: 30 mM). Line graphs represent the 
average fluorescent calcium signal in dendrites over time from (a) wildtype (WT) 
and (b) Fmr1 KO mice. Baseline was established for 1 minute before the addition 
of the GABABR agonist baclofen (Bac: 50 µM) in vehicle- or ethanol-exposed 
neurons. Baclofen was allowed to equilibrate as indicated by the break between 
dotted lines. (c) Summary graph shows significant increase in dendritic calcium 
signal (ΔF/F) with the addition of baclofen in WT neurons pre-treated with 
ethanol, which was not observed in Fmr1 KO neurons. WT: Veh+Bac= -11.82 ± 
3.55, n=8; ETOH+Bac=9.10 ± 1.65, n=14.  Fmr1 KO : Veh+Bac=2.81 ± 1.48, 
n=12; ETOH+Bac=3.74 ± 1.30, n=12. (d-e) Dendritic calcium imaging was 
performed as before in hippocampal cultured neurons infected with either vector 
(rAAV:mSYN-tdTomato) or FMRP overexpression (rAAV:mSYN-FMRP and 
rAAV:mSYN-tdTomato). Ethanol-induced increase in dendritic calcium is 
prevented by FMRP overexpression. Vector: Veh+Bac: -6 ± 1.6, n=17 dendrites; 
ETOH+Bac: 2.5 ± 2.5, n=17 dendrites. FMRP overexpression: Veh+Bac: -4 ± 2, 
n=11 dendrites; ETOH+Bac: -4.7 ± 1.4, n=27 dendrites. Significance determined 
by two-way ANOVA, followed by Tukey’s multiple comparison. Values represent 
mean ± SEM. 
 
Antidepressant effect of ethanol on behavior requires FMRP  
 
Since FMRP is important for ethanol-induced GABABR plasticity, we examined 
antidepressant and anxiolytic-like effects of ethanol on behavior in Fmr1 KO 
mice. Interestingly, ethanol administration did not affect the behaviors of Fmr1 
KO mice in the splash and open field tests compared to saline-treated mice 
(Supplementary Fig. 2.6a-e). Surprisingly, the basal state of immobility in the 
FST in Fmr1 KO mice is equivalent to ethanol-injected WT mice (Fig. 2.8). To 
explore this paradox, we examined the requirement of GABABR activation in 
ethanol-induced decreases in immobility by using CGP-35348 to inhibit 
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postsynaptic GABABRs. We previously showed that GABABR antagonism 
blocked the antidepressant-like behavior produced by NMDAR antagonist in the 
FST13. GABABR inhibition alone did not affect the immobility of saline-injected 
WT mice in the FST, similar to what we observed previously (Fig. 2.8)13. CGP-
35348, however, abolished the ethanol-induced antidepressant behavior, 
demonstrating a requirement for GABABR activation in ethanol-triggered 
reduction of immobility. Neither ethanol, CGP-35348, or ethanol + CGP-35348 
treatment in Fmr1 KO mice produced immobility scores that were significantly 
different from saline-treated Fmr1 KO mice. These findings collectively 
demonstrate that GABABRs and FMRP are necessary to elicit the ethanol-
mediated antidepressant response.  
 
     
Figure 2.8. Ethanol’s antidepressant effect requires GABABR activation 
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Wildtype (WT) C57BL/6 and Fmr1 KO male mice were subjected to the forced 
swim test (FST) 24 hours post-injection of vehicle (Veh: saline), ethanol (ETOH: 
2.5 g kg-1), CGP-35348, a GABABR antagonist (CGP: 100 mg kg-1), or 
ethanol+CGP-5348. Ethanol induced-decrease in immobility was absent in Fmr1 
KO mice. WT: Veh=100 ± 3.19 s, n=9 mice; ETOH=72.97 ± 6.23 s, n=7 mice; 
CGP-35348=98.38 ± 4.2 s, n=10; ETOH+CGP-35348=94.73 ± 3.77 s, n=7 mice.  
Fmr1 KO : Veh=58.75 ± 10.33 s, n=9; ETOH=69.02 ± 8.99 s, n=3; CGP-
35348=88.00 ± 9.56 s, n=3; ETOH+CGP-35348=77.78 ± 16.04 s, n=3. 
Significance determined by two-way ANOVA Tukey’s multiple comparison test. 
Values represent mean ± SEM.  
 
Discussion 
Emerging behavioral and molecular evidence demonstrate that NMDAR 
antagonists act as rapid antidepressants13, 70, 74, 78, 157. Because it has long been 
speculated that individuals with major depressive disorders self-medicate with 
alcohol, we examined whether ethanol, which blocks NMDARs52, acts through 
the same synaptic pathways as NMDAR antagonists. Until this study, the 
molecular mechanisms shared by alcohol and antidepressants were unexplored. 
Here, we provide molecular and behavioral evidence that acute alcohol exposure 
elicits antidepressant-like behaviors that persist up to 24 hours after 
administration (Fig. 2.1), supporting the hypothesis that ethanol initiates lasting 
antidepressant activity. We have previously demonstrated that NMDAR inhibition 
by rapid antidepressants induces two key molecular changes that are 
responsible for the rapid antidepressant response, namely (1) an increase in 
GABABR protein synthesis and (2) a shift in GABABR function that increases 
dendritic calcium signaling13, 78. Our current work shows that these same 
signature changes are produced by acute ethanol exposure (Fig. 2.5-2.7).   
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Surface expression of functional GABABRs requires the dimerization of 
GABABR1 and R2 subunits. Without GABABR2, GABABR1 is retained in the 
endoplasmic reticulum153. Our current studies show that the release of GABABR2 
mRNA translational repression by FMRP is necessary for the ethanol-induced 
increase in surface GABABRs with NMDAR blockade (Fig. 2.4,2.6,2.8, 
Supplementary Fig. 2.3). Reduction of FMRP, as seen in animal models of FXS, 
is associated with elevated protein synthesis of target mRNAs87. While we have 
demonstrated that FMRP associates with GABABR1 and R2 mRNAs, the loss of 
FMRP has a profound effect on GABABR2 protein expression in dendrites. 
Constitutive loss of FMRP, as observed in many of its targets, abrogates 
stimulus-dependent mRNA transport and translation of target mRNAs88, 137, 158, 
159. We show that the ethanol-induced increase in GABABR2 protein is also 
absent in Fmr1 KO mice.  
The question of why GABABR2 is uniquely affected by acute ethanol and 
its dependence on reduced FMRP levels is intriguing. Both GABABR1 and 
GABABR2 mRNA were detected in the FMRP RIP (Fig. 2.3). Interestingly, in vivo 
FMRP influences GABABR1 expression to a lesser extent compared to 
GABABR2, suggesting that FMRP may act in concert with other repressors such 
as microRNAs to tightly regulate GABABR1 expression160. Moreover, our 
immunostaining and protein synthesis assays suggest that the increased protein 
levels of GABABR1 are not due to new protein synthesis in the dendrites, even in 
Fmr1 KO mice (Fig. 2.5 and 2.6). These results indicate that the overall increase 
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in synaptic GABABR1 expression in Fmr1 KO mice may be due to an increase in 
presynaptic GABABR1 expression, either through protein synthesis or increased 
protein stability. Notably, FMRP has been localized to axons and presynaptic 
terminals161, 162. Further exploration into presynaptic and postsynaptic GABABR 
expression and function in AUD and FXS is warranted. 
The “GABA hypoinhibition theory” posits that loss of inhibition is a leading 
cause in many of the neurological symptoms observed in FXS163. While studies 
showing reduced inhibition in models of FXS have focused on decreased 
expression of GABAAR subunit mRNA and protein164, GABABR protein 
expression and dendritic signaling has not been explored. Interestingly, the 
GABABR agonist baclofen has shown promise in treating FXS. (R)-baclofen 
administration in vitro corrects the elevated basal protein synthesis normally seen 
in Fmr1 KO mice, and rescues synaptic abnormalities such as increased spine 
density165. Additionally, baclofen administration reduced symptoms related to 
FXS in Fmr1 KO mice165, 166. Recent studies have shown that the excitatory drive 
to fast spiking inhibitory neurons is reduced in the cortex of Fmr1 KO mice167. 
Our data expands upon these findings by suggesting that postsynaptic GABABR 
coupling to inwardly rectifying G protein-coupled potassium channels (GIRK) is 
absent in Fmr1 KO neurons (Fig. 2.7). Collectively, these results may imply that 
the therapeutic effects of baclofen in the Fmr1 KO mouse may be due to 
activation of presynaptic GABAB receptors that may in turn reduce glutamate 
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release and reduce hyperactive metabatropic glutamate receptor mGluR 
signaling in the hippocampus168.  
Changes in gene expression and protein synthesis are essential for 
normal neuroplasticity, but these crucial processes are dysregulated by drug 
addiction134, 169. Several lines of evidence support parallel changes in GABABR 
mRNA translation/signaling as a result of NMDAR blockade that may be critical 
for alcohol actions. First, NMDAR antagonists mimic some effects of ethanol in 
humans170, suggesting common biochemical/electrophysiological signaling 
pathway(s). Second, changes in GABABR2 brain gene expression correlates with 
lifetime alcohol consumption, supporting a role for altered GABABR signaling in 
AUD112. Third, although controversial, the GABABR agonist baclofen may 
decrease alcohol consumption in some alcoholics171. In summary, our data 
defines a common molecular paradigm for alcohol and rapid antidepressants and 
identifies a mechanism for the initial antidepressant effects of alcohol. A shift in 
GABABR signaling is observed with both rapid antidepressants and acute ethanol 
treatment, which may provide insight into the molecular basis for the high 
comorbidity between major depressive disorder and AUD.  
CHAPTER 3: ACUTE ALCOHOL AND RAPID ANTIDEPRESSANT 
INFLUENCE ON THE SYNAPTIC TRANSCRIPTOME 
Abstract 
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Alcohol use disorder (AUD) and major depressive disorder (MDD) are prevalent, 
debilitating, and highly comorbid. The dual development of these disorders has 
been speculated, but underlying molecular changes that could account for the 
high rate of comorbidity are undetermined. Recent evidence suggests that acute 
alcohol exposure has rapid antidepressant behavioral and molecular properties. 
To explore parallels between alcohol and rapid antidepressants on a genomic 
scale, we interrogated transcriptional changes induced with acute treatment of 
ethanol or the N-methyl-D-aspartate receptor (NMDAR) antagonist, Ro 25-6981 
in hippocampal synapses. Ethanol and Ro 25-6981 distinctly altered differential 
gene expression with only select genes exhibiting similar changes in expression, 
and acute ethanol exposure induced alterations in gene expression largely 
independent of NMDAR antagonism.  To explore parallel alterations between 
ethanol and Ro 25-6981 treatment that alter synaptic function, but not 
necessarily gene expression, we interrogated differential exon usage. Notably 
both ethanol and antidepressant induced similar alterations in exon usage, 
suggesting that ethanol and rapid antidepressants induce differential splicing of 
synaptic related genes. Additionally, predominant genes associated with 
alternative splicing in AUD and MDD were identified within differential exon 
expression data with both ethanol and Ro 25-6981. Finally, our analysis 
highlights the profound effect acute NMDAR inhibition exerts on differential exon 
use at the synapse.  This altered exon use likely contributes to the mechanism of 
acute Ro 25-6981 and other NMDAR antagonists providing important context for 
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their biological and pharmacological implications. These data implicate 
alternative splicing and isoform expression in the acute antidepressant-like 
effects of ethanol and the development of comorbid alcohol and depression. 
Understanding the molecular basis for comorbidity may aid in development of 
treatment options for afflicted individuals with dual disorders, as well as explore 
the mechanism for the initiation of addiction with acute exposure to alcohol. 
Introduction 
 
Alcohol use disorders display high comorbidity with other psychiatric disorders in 
particular major depressive disorder. The relationship between AUD and MDD is 
not fully understood, but the two disorders are closely linked through 
epidemiological and clinical studies14, 36, 38. The connection between AUD and 
MDD may be caused by similar environmental and genetic factors14, 36, 38. The 
self-medication hypothesis proposes that depressed individuals drink to alleviate 
symptoms initially, but chronic use leads to comorbid AUD. This chronic abuse 
can induce neuroadaptive changes manifesting as tolerance and physiological 
dependence1. In particular, synaptic remodeling in response to alcohol is thought 
to lead to tolerance and physical dependence with continued alcohol abuse2. 
Some studies suggest that alcohol and other addictive drugs alter molecular 
mechanisms underlying synaptic plasticity45, 136, and drug induced changes in 
gene expression are proposed as critical molecular adaptations leading to 
addiction with repeated exposure60. These initial changes in synaptic remodeling 
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may be key to understanding the development of comorbid AUD. Our previous 
studies in animals have identified that acute alcohol and antidepressant can elicit 
the same synaptic signaling pathway, thought to lead to activation of synaptic 
plasticity related pathways79. Alcohol was also shown to induce a lasting 
antidepressant like response in behavioral assays for antidepressant efficacy79. 
To address the continued mystery surrounding the acute antidepressant effects 
of ethanol and the development of comorbid AUD and MDD, we sought to 
identify acute alcohol and antidepressant effects on a global scale by analyzing 
parallels between the acute ethanol and rapid antidepressant synaptic 
transcriptome.  
Alcohol and other drugs of abuse promote profound changes in gene 
expression, mRNA translation rates, and synaptic protein composition134, 135. 
Genome-wide expression studies show that transcriptional profiling is important 
to understand brain effects of alcohol exposure in both humans and mice. RNA-
Sequencing (RNA-Seq) analysis of postmortem brain tissue from human 
alcoholics revealed that differences in transcriptome organization is linked with 
lifetime consumption of alcohol112. Both MDD and rapid antidepressants alter the 
transcriptome of humans and animals. RNA-Seq studies of postmortem 
depressed human tissues find altered expression of genes with MDD, and MDD 
suicides118, and enrichment for particular synapse related genes in human MDD 
tissues119. Analysis of gene regulation of rat hippocampus treated acutely with 
antidepressants identified a variety of genes involved in various cellular 
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processes suggesting that the therapeutic effect is very complex120. It is evident 
that both AUD and MDD alter gene expression, however little is known about 
their acute effects on the transcriptome and even less is known about shared 
alterations in gene expression between these two disorders.  
The effect alternative splicing has on acute alcohol or antidepressant 
behavior is undetermined. This is an important avenue of study because, 
alternative splicing can generate isoforms that differ in function and 
localization110, and these Isoforms can be important for development, 
differentiation, and disease110. Alternative splicing and exon composition play an 
important role in the complexity of the proteome and are widely implicated in 
physiological and pathophysiological processes172-174. Alternative splicing can 
induce altered exon expression and composition in RNA, allowing new protein 
isoforms to be translated without observed alterations of basal mRNA or protein 
expression. Ethanol exposure has been shown to affect splice patterning of 
several transcripts including NMDAR121, γ-aminobutyric acid type A receptor 
(GABAAR)122, and γ-aminobutyric acid type B receptor (GABABR)123, however, 
transcriptome-wide RNA-Seq has not been used to define synaptic effects of 
acute alcohol exposure. Differential exon usage occurs in individuals with MDD 
with the strongest evidence for splicing in ATPase class II type 9B (ATP9B) and 
eukaryotic translation initiation factor 3 subunit K (EIF3K) genes118.  The 
significance of splice patterning in AUD and MDD in development of these 
disorders, or the effects that altered isoforms may have on neuroadaptation with 
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alcohol is unknown.  In addition to identifying parallel gene expression changes 
between ethanol and rapid antidepressant; we sought to identify altered exon 
usage to further investigate possible shared transcriptome changes that may 
lead to altered synaptic function through isoform expression. 
We focused on alterations in the hippocampus due to previous studies of 
ethanol and antidepressants affecting this brain region. Studies of human 
hippocampus demonstrate that this brain region shows changes in transcription 
patterns with chronic drinking60, 113. Animal studies of rapid antidepressants, 
including ketamine, identified altered gene expression after as little as one dose 
in the hippocampus and other brain regions95. Additionally, our previous work 
identified shared molecular mechanisms induced by both ethanol and rapid 
antidepressant in the hippocampus79. Additionally, we selected the rapid 
antidepressant Ro 25-6981 for it’s highly selective and potent inhibition of the 
NR2B subunit of the NMDAR31, 32 as opposed to other rapid antidepressants that 
some of which have adverse side effects27, or alternative convoluting 
mechanisms of action175.  
RNA sequencing allows for the detection of most mRNAs, including those 
that map to the same gene due to splice variation176. RNA sequencing paired 
with differential expression tools like DEXSeq can provide information on 
differential exon-usage of gene products177.  Here we applied next generation 
RNA sequencing to identify the differentially expressed genes (DEGs) and 
differentially expressed exons (DEEs) for mice treated acutely with alcohol or the 
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rapid acting antidepressant, Ro 25-6981. We isolated RNA from hippocampal 
synaptoneurosomes to evaluate parallel gene and exon usage patterns between 
acute alcohol and antidepressants that may play a role in synaptic plasticity. Our 
results suggest that limited parallel alterations in gene expression occur between 
both ethanol and Ro 25-6981 acute treatment; however, exon usage analysis 
showed pronounced alterations with both treatments and an abundance of 
shared genes containing DEEs between both treatments.  
Methods 
Animals 
 
Male C57BL/6NCrl mice at least 8 weeks old were given intraperitoneal (i.p.) 
injections of 200 µl vehicle (saline), ethanol (2.5 g kg-1 in saline), or Ro 25-6981 
(10 mg kg−1 in saline, Tocris). All animals were housed 4 mice per cage. All 
treatments were administered to one mouse per home cage. At the time of drug 
treatment, animals were coded by number. Animals were sacrificed 30 minutes 
after inject to harvest tissue. Hippocampi was immediately flash frozen in liquid 
nitrogen after dissection.  All experiments were carried out in accordance with 
the National Institutes of Health’s Guide for the Care and Use of Laboratory 
Animals and approved by the UT-Austin Institutional Animal Care and Use 
Committee (IACUC). 
Synaptoneurosome preparation and RNA isolation 
 
 79 
RNA was isolated from hippocampal synaptoneurosomes (SN) prepared from 
male mice age 7-8 weeks treated with vehicle (saline), Ethanol (2.5g kg−1), or Ro-
25-6981 (10 mg kg−1) as previously described. SNs were prepared by 
homogenizing hippocampal tissue in homogenization buffer (20 mM HEPES pH 
7.4, 5 µM EDTA pH 8.0, and RNase inhibitor). Homogenate was filtered through 
a 100-µm nylon filter followed by a 5-µm filter, and centrifuged at 14000 x g for 
20 minutes at 4oC142. The pellet was resuspended in Buffer RLT for processing 
with an RNeasy micro Kit (Qiagen, 74004). RNeasy micro kit procedure was 
followed as supplied by the company. Briefly, sample was homeginzed in RLT 
buffer. 1 volume of 70% ethanol was added to precipitate RNA and sample was 
centrifuged for 15 seconds at 8000xg in microcentrifuge through RNeasy 
MinElute spin column. Buffer RW1 was added to column and centrifuged as 
before. Sample was DNAse treated and centrifuged as before with buffer RW1. 
Column was then washed in buffer RPE and spun as before. Column was dried 
by adding 80% ethanol and centrifuging for 2 minutes at 8000 xg and then again 
with column lid open for 5 min at full speed. RNA was then eluted in nuclease 
free water. RNA quality was determined using a 2200 AgilentTapeStation 
Instrument(Agilent Technologies, G2965AA), and yield was determined using 
Qubit fluormetric quantitation (ThermoFisher, Q33216). 
RNA-Sequencing  
 
RNA samples were sequenced by the genome sequencing and analysis facility 
at the University of Texas at Austin. Poly-A-mRNA was captured with 
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MicroPoly(A) Purist Kit (Life Technologies). Samples were processed with whole 
transcriptome library preparation kit (NextSeq 500/550 High Output Kit, FC-404-
2002) and sequenced on a NextSeq 500 system (Illumina) at a depth of 
~20million reads with paired-end reads. Read quality was assessed using 
FASTQC (version 0.11.5). One ethanol treated sample was discarded due to low 
sequencing reads. Sequencing reads were mapped to the mouse genome (Mus 
musculus version GRCm38 rel.80, Ensemble) with Splice Transcripts Alignment 
to a Reference (STAR, version 2.5.0a). HTSeq (version 0.5.3p9) was used to 
quantify raw counts178, followed by DESeq2 (version 1.14.1) to identify 
differentially expressed genes with treatment179, and DEXSeq (version 1.20.2) to 
identify differentially expressed exons177, 180. Enrichment analysis for gene 
ontologies was preformed with Enrichr181, 182. Data processing and statistics was 
preformed with R programming146.  
Results  
 
Ethanol and Ro 25-6981 treatment induce differential expression of genes  
 
Ethanol and the rapid antidepressants Ro 25-6981 display some similar features 
acutely including: the induction of synaptic plasticity related pathways96, acute 
inhibition of the NMDAR52, 74, 183, lasting antidepressant like behavioral responses 
in mice78, 79, and altered gene expression95. To better understand these similar 
phenomena of the acute effects of both ethanol and rapid antidepressant, we 
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investigated the synaptic transcriptome through RNA sequencing of hippocampal 
synaptoneurosomes of mice treated acutely (30 minutes) with ethanol (2.5g kg−1) 
or Ro 25-6981 (10 mg kg−1).  
The differential gene expression analysis tool DESeq2 was used to detect 
genes significantly altered by ethanol exposure (Fig 3.1a) and Ro 25-6981 
exposure (Fig. 3.1b). For quality control purposes, isolation purity, batch affect, 
and sample outliers were assessed. Synaptoneurosome preparations were 
assessed for purity and were highly enriched in synaptic genes (Supplemental 
Fig. 3.1). No differences in batch effect were identified when assessed with 
principle component analysis (PCA; supplemental Fig. 3.2), and no sample 
outliers were detected with hierarchical clustering and correlation plotting 
(Supplemental Fig. 3.3). 
Differentially expressed genes were identified between saline and ethanol 
or Ro 25-6981 treatment. DEGs were plotted in volcano plots comparing p-value 
and fold-change for each gene, and colored points indicate DEGs with a 
significance bellow 0.05. With ethanol treatment 1031 genes were identified as 
significantly differentially expressed (red), and with Ro 25-6981 treatment 2623 
genes were identified (yellow). Cellular component gene ontologies were 
assessed for these DEGs with ethanol treatment (Fig. 3.1c) and Ro 25-6981 
treatment (Fig. 3.1d) using the enrichment ontology tool Enrichr181, 182. With both 
ethanol and Ro 25-6981 treatments, we observed ontologies highly enriched for 
synaptic genes as expected from the hippocampal synaptoneurosomes (Fig. 
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3.1e-f). We identified parallels between the alcohol and antidepressant DEGs by 
examining the genes altered in both treatments. There were 178 shared genes 
differentially expressed with both treatments, comprising ~17% of the ethanol 
induced DEGs and ~7% of the Ro 25-6981 induced DEGs (Fig. 3.1e). These 
DEGs were enriched for synaptic and dendritic genes as well as those involved 
in protein kinase signaling (Fig. 3.1f). The observed alterations in these synaptic 
ontologies may indicate alterations in synaptic function with both treatments.  
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Figure 3.1. RNA-seq results of differentially expressed genes (DEGs) from 
synaptoneurosomes 
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C57Bl/6 mice were treated with vehicle (saline; n=8), ethanol (2.5g/kg; n=7), or 
Ro 25-6981 (10mg/kg; n=8). a) Volcano plot of differentially expressed genes 
with ethanol (n=7) compared to vehicle (saline, n=8) reveal a significant number 
of genes (1031; red) both up- and down-regulated with ethanol exposure shown 
as positive of negative log2fold change with treatment (p ≤ 0.05). b) Volcano plot 
of differentially expressed genes with Ro 25-6981 compared to vehicle reveal a 
significant number of genes (2623; yellow) both up- and down-regulated with Ro 
25-6981 exposure shown as positive of negative log2fold change with treatment 
(p≤0.05). c) Cellular component gene ontologies for DEGs (p ≤ 0.05) with ethanol 
were identified with Enrichr gene enrichment analysis software. The 5 most 
significant ontologies determined by p value are shown in the summary bar 
graphs. d) Cellular component gene ontologies for DEGs (p ≤ 0.05) with Ro 25-
6981. The 5 most significant ontologies determined by p value are shown in the 
summary bar graphs. e) Venn diagram compared DEGs found in ethanol and Ro 
25-6981 treatment groups, and found 178 genes that overlapped between both 
treatment groups (p ≤0.0001), suggesting these genes may be implicated in the 
acute antidepressant like effects of alcohol exposure. f) Cellular component gene 
ontologies for these 178 overlapping DEGs were identified with Enrichr gene 
enrichment analysis software. The 5 most significant ontologies determined by p 
value are shown in the summary bar graphs. 
 
 
 To examine these findings further we investigated the co-occurring DEGs 
for up-regulation and down-regulation for both treatments. A heat map of the fold 
change of the 178 overlapping DEGs was generated where red indicates up-
regulation and blue down-regulation (Fig. 3.2a), and many genes were observed 
to have opposite directionality. We identified 50 genes with parallel expression 
patterns, meaning they were either up-regulated (Fig. 3.2b) in both treatment 
groups, or down-regulated (Fig. 3.2c) in both treatment groups. The limited 
parallel effects we observed with DEGs between ethanol and Ro 25-6981 may 
be due to alternative targets of ethanol in neurons, and differences in binding 
specificity and affinity between ethanol and Ro 25-6981 for the NR2B subunit of 
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the NMDAR. Our data emphasizes the selective and potent binding of Ro 25-
6981 to the NR2B subunit compared to ethanol. Where Ro 25-6981 is a highly 
selective noncompetitive antagonist of the NR2B subunit32, 33, 184, ethanol 
transiently inhibits NMDARs, and affects many other cellular targets45, 185. 
NMDAR inhibition with acute ethanol exposure is thought to affect synaptic 
plasticity96, 186, 187, conversely most of our DEGs with ethanol are not conserved 
with NR2B antagonism. To explore this further we analyzed ethanol induced 
DEGs independent of NR2B antagonism.  
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Figure 3.2. Parallel expression of DEGs with ethanol and antidepressant 
 
DEGs in each treatment group were compared for similarities in fold change 
directionality using a heat map of log2fold changes. a) The log2fold changes of 
the 178 co-occurring DEGs between ethanol and Ro 25-6981 were clustered and 
visualized in a heat map. Scale bar indicates log2fold changes ranging from blue 
(down-regulated with negative fold change) to red (up-regulated with positive fold 
change). b) Simultaneously occurring up-regulated DEGs in both treatment 
groups were plotted together in a heat map with gene labels displayed. Scale 
indicates positive log2fold changes. c) Simultaneously occurring down-regulated 
DEGs were plotted together in a heat map with gene labels displayed. Scale 
indicates negative log2fold changes. 50 genes were identified to have similar 
regulation between both ethanol and Ro 25-6981 treatment. 
 
Alcohol induced differential gene expression is largely independent of NR2B 
inhibition 
 
Our results suggest that many transcriptome changes produced by acute ethanol 
were largely independent of NR2B antagonism. By removing those DEGs 
associated with Ro 25-6981 induced alterations we isolated ethanol induced 
DEGs not directly related to NMDAR inhibition. We identified 853 DEGs 
independent of NR2B antagonism (Fig. 3.3a). These genes displayed molecular 
function gene ontologies enriched for mRNA 3’UTR binding, mRNA binding, and 
MAPK signaling (Fig. 3.3b).  RNA binding proteins are crucial for the trafficking of 
mRNAs to synapses and influence protein translation that underlies synaptic 
plasticity85, 86.  Furthermore, mitogen-activated protein kinase (MAPK) signaling 
also plays a key role in regulating transcription and synaptic plasticity188. These 
ontologies may indicate an increased role in mRNA trafficking and local 
translation in synapses. The modulation of genes with these ontologies likely 
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contributes to the synaptic changes seen upon both acute ethanol treatment and 
after repeated exposures189. The DEGs with the greatest fold changes are 
displayed in a bar graph with red and blue bars indicating up- and down-
regulated directionality respectively (Fig. 3.3c). These genes contain several 
protein coding genes involved in RNA binding and MAPK signaling188 (Fig. 3.3c). 
A similar graph for genes associated with Ro 25-6981 is displayed in 
Supplemental Fig. 3.4. Alterations in gene expression were observed with acute 
ethanol and Ro 25-6981 treatment independently, but simultaneous gene 
expression alterations with both treatments were limited. Alterations in synaptic 
plasticity and synaptic function have been identified for both alcohol80, 96, 186, 187 
and rapid antidepressants13, 76, 190, 191, therefore we sough to find an answer to 
why parallel transcriptional changes were not robust in our analysis by exploring 
differential exon usage that could direct expression of alternative protein 
isoforms. 
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Figure 3.3. Ethanol DEGs independent of NR2B antagonism 
 
DEGs with Ro 25-6981 treatment were removed from the DEGs with ethanol 
treatment (p ≤0.05), to identified transcriptional changes independent of NMDAR 
inhibition. a) The Venn diagram illustrates that 853 genes are differentially 
expressed with ethanol (p ≤0.05) independent of the 178 genes that are also 
differentially expressed with NR2B inhibition (p ≤0.05), suggesting these genes 
may be implicated in acute ethanol alterations independent of NMDAR inhibition. 
b) Molecular component gene ontologies for these 853 DEGs were identified with 
Enrichr gene enrichment analysis software. The 5 most significant ontologies 
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determined by p value are shown in the summary bar graphs. c) Summary bar 
graph indicates the top 10 up- and down-regulated genes according to log2fold 
change identified with acute ethanol independent Ro 25-6981 DEGs. Blue 
indicates down-regulated while red indicates up-regulated fold changes. 
 
 
Alcohol and rapid antidepressant induce differential exon usage 
 
To address the hypothesis that RNA splicing may be altered by alcohol and 
antidepressant treatments, we utilized DEXSeq to detect differentially expressed 
exons (DEEs). Many exons were differentially expressed with both ethanol and 
Ro 25-6981 as indicated by the summary bar graph (Fig. 3.1a).  Corresponding 
volcano plots of exon expression for both ethanol and Ro 25-6981 show fold 
change variability and significant genes as colored points (Supplemental Fig. 
3.4). DEEs for ethanol and Ro 25-6981 treatment were compared to identify co-
occurring single exon changes with each treatment, and a significant population 
of exons were identified (Fig. 3.4b). We identified the genes where these exon-
specific changes originated, summarized the number of significant genes with 
DEEs in a bar graph (Fig. 3.4c), and then overlapped these genes to identify 
those with co-occurring significant alternative exon use with both ethanol and Ro 
25-6981. We discovered 2976 genes with alternative exon use with ethanol 
exposure, and 6082 genes with alternative exon use with Ro 25-6981. We then 
identified 1630 shared genes with alternative exon use in both ethanol and Ro 
25-6981 treated mice, comprising ~55% of the ethanol induced genes with DEEs, 
and ~27% of the Ro 25-6981 induced genes with DEEs (Fig. 3.4d). These 1630 
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overlapping genes were enriched for cellular component gene ontologies linked 
to cytosolic and synaptic associated genes (Fig. 3.4e). These alternative exons 
may lead to alterations in synaptic isoforms contributing to the synaptic plasticity 
and alterations in synaptic activity observed with ethanol and rapid 
antidepressants79. This is in line with previous studies demonstrating altered 
isoforms in individuals with MDD or AUD118, 125, diseases hallmarked by altered 
synaptic function and neuroadaptation76, 96. Our analysis revealed pathway 
ontologies enriched for genes associated with GTPase binding and ATP binding, 
including ATP9B (Fig. 3.4f) a gene previous implicated in MDD118.  Specifically, 
ATP9B and EIF3K genes undergo extensive exon use alterations in both MDD 
individuals, and in the present study, upon acute ethanol and Ro 25-6981 
treatment.  Furthermore, we identified several genes with DEEs previously found 
to have alternative splice patterning in AUD including key synaptic receptors 
such as NDMAR121 and GABABR123.  These and other genes identified in our 
analysis represent novel genes that may contribute to the high degree of 
comorbidity observed between AUD and MDD.  This overlap may reveal new 
treatment avenues for individuals suffering from comorbid AUD and MDD and 
allow for the development pharmacological intervention.  Finally, our analysis 
highlights the effect acute NR2B inhibition exerts on differential exon use at the 
synapse.  This altered exon use likely contributes to the mechanism of Ro 25-
6981 and other NMDAR antagonists providing important context for their 
biological and pharmacological implications. 
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Figure 3.4. RNA-seq results of differentially expressed exons (DEEs) from 
synaptoneurosomes 
 
mice  (C57BL/6) were acutely treated with vehicle (saline; n=8), ethanol (2.5g/kg; 
n=7), or Ro 25-6981 (10mg/kg; n=8). a) Summary bar graph illustrates the total 
number of DEEs found with ethanol (13770; red) and Ro 25-6981 (11881; yellow) 
treatment (p ≤0.05). b) Venn diagram compared DEEs found in ethanol and Ro 
25-6981 treatment groups, and identified 1609 exons that overlapped between 
both treatment groups (p ≤0.0001), suggesting these exons may be implicated in 
the acute antidepressant like effects of alcohol exposure. c) Genes containing 
differentially expressed exons were identified. The number of genes with DEEs 
for ethanol (2976; red) and Ro 25-6981 (6082; yellow) acute treatment were 
identified and displayed in the summary bar graph. d) Venn diagram compared 
genes with DEEs found in ethanol (red) and Ro 25-6981(yellow) treatment 
groups, and identified 1630 genes with DEEs that overlapped between both 
treatment groups (p ≤0.0001), suggesting these exons may be implicated in the 
acute antidepressant like effects of alcohol exposure. e) Molecular component 
gene ontologies for these 1630 overlapping genes with DEEs were identified with 
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Enrichr gene enrichment analysis software. The 5 most significant ontologies 
determined by p value are shown in the summary bar graph. f) Cellular 
component gene ontologies for these 1630 overlapping genes with DEEs were 
identified with Enrichr gene enrichment analysis software. The 5 most significant 
ontologies determined by p value are shown in the summary bar graph. 
 
 
Acute alcohol and Ro 25-6981 induce differential exon use in genes implicated in 
AUD and MDD 
 
To take a closer look at differential exon usage produced by ethanol and Ro 25-
6981, we focused on genes previously identified for their importance in splice 
variation with AUD (NMDAR), and MDD (ATP9B). DEEs appear with both 
treatments for Grin1, which encodes the NR1 subunit of the NMDAR (Fig. 3.5a-
b).  Ethanol induces an up-regulation in the expression of exon 5, which encodes 
the N1 splice cassette in some NR1 isoforms, and Ro 25-6981 induced an up-
regulation in exon 4. The N1 splice cassette forms a surface loop, which can 
affect affinities for NMDA and glutamate124, 192, potentiate receptor function193, 
and accelerate the deactivation time course of NR1194. Studies of the modulation 
of NR1 splice variants with ethanol found differential exon 5 expressions, but 
reports are inconsistent and differ with dose, time, and brain region125. It is 
possible that differential exon use in this region of NR1 occurs with acute ethanol 
to counteract the inhibitory effects on the NMDAR. Both exon 4 and exon 5 are 
located in a ligand-binding domain of the NMDAR in mice, and alterations in this 
region may alter function of the synaptic NMDAR with ethanol and Ro 25-6981. 
Splice variants observed in the c-terminal domain of the NR1 can affect 
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localization and endoplasmic reticulum retention, affecting surface expression195. 
Differential exon expression in this region may increase surface targeting of NR1, 
and ethanol exposure altered exon use in this region of Grin1 (Fig. 3.5a); 
however more research is necessary to identify the effects of the differential 
regulation of these exons.  
ATP9B encodes the ATPase Class II Type 9B protein, and has been 
implicated in pathways related to ion channel transport196. Ethanol and Ro 25-
6981 acute treatment both induced DEE in the ATP9B gene; however, ethanol 
and Ro 25-6981 did not affect expression of the same exons (Fig. 3.5c-d). This 
may be a product of the differences between ethanol and Ro 25-6981 binding 
specificity and affinity. The pathophysiological consequences of ATP9B 
alternative splicing are unknown. It is critical to note that common DEEs can be 
discovered between acute treatments of ethanol and rapid antidepressant in 
mice that correspond the same genes with DEEs in AUD and MDD in humans. 
By examining different isoforms it may be possible to discover other targets to 
investigate underlying changes associated with the high comorbidity of AUD and 
MDD in humans.  
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Figure 3.5. Expression of exons in NR1 and ATP9B with ethanol and Ro 25-
6981 treatment 
 
a-b) Graph represents normalized exon expression on the x-axis with exon IDs 
on the y-axis, and bellow the exon IDs is a NR1 transcript with corresponding 
gene locations labeled bellow. The dotted blue line represents vehicle (saline) 
while the red dotted line represents either ethanol expression or Ro 25-6981 
expression. a) Red exons on the NR1 transcript indicate those significantly 
differentially expressed with ethanol treatment. b) Yellow exons on the NR1 
transcript indicate those significantly differentially expressed with Ro 25-6981 
treatment (p ≤0.05). c-d) Graph represents normalized exon expression on the x-
axis with exon IDs on the y-axis, and bellow the exon IDs is a ATP9B transcript 
with corresponding gene locations labeled bellow. The dotted blue line 
represents vehicle (saline) while the red dotted line represents either ethanol 
expression or Ro 25-6981 expression. a) Red exons on the ATP9B transcript 
indicate those significantly differentially expressed with ethanol treatment. b) 
Yellow exons on the ATP9B transcript indicate those significantly differentially 
expressed with Ro 25-6981 treatment (p ≤0.05). 
 
 
Discussion  
 
NMDAR antagonists have gained acceptance as rapid acting antidepressants. 
Their fast acting and long lasting effects are due in part to alterations in synaptic 
plasticity and synaptic protein composition70, 74, 78. Alcohol induces similar 
antidepressant-like effects in behavioral tests for antidepressant efficacy and 
induced synaptic signaling pathways that could lead to plasticity79. Continued 
alcohol abuse may induce neuroadaptive changes to counteract these initial 
effects, and the self-medication hypothesis suggests that the initial 
antidepressant effects of alcohol will shift to depressant allostatic states with 
continued abuse leading to addiction101. Despite the high comorbidity of AUD and 
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MDD14, the underlying mechanism for the dual development of these disorders is 
relatively unknown. In this study we investigated the synaptic transcriptome, 
hypothesizing that parallel alterations in synaptic gene expression would occur 
with acute ethanol and rapid antidepressant treatment.  
 We identified differential gene expression shared by ethanol and Ro 25-6981 
treatments, but found that many transcriptional changes are distinct within the 
two treatments. We discovered that ethanol induced gene expression changes 
are largely independent of acute NR2B inhibition, emphasizing the important of 
investigating novel targets. We also predict that the dissimilarities observed 
between ethanol and Ro 25-6981 may be due to the potent and selective nature 
of Ro 25-6981 or the time point that we chose. Ethanol may induce greater and 
more pronounced gene expression changes with increased treatment time, as 
chronic ethanol consumption is known to produce more changes in gene 
expression in synaptoneurosomes than we found here197. More similarities 
between ethanol and Ro 25-6981 may also be observed with longer treatment 
times. One hypothesis to explain this phenomena is that altering the abundance 
of splice variants at the synapse, through either localization of previously 
transcribed RNAs or alternative splicing of de novo transcripts generated from 
transcriptionally active genes, may occur more rapidly than reprogramming of 
transcriptional routines to alter the steady state levels of different transcripts 
apparent in chronic AUD.  
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 Our data suggest that isoform differences may be a key player in the inducing 
the molecular and behavior changes observed with acute ethanol and rapid 
antidepressant treatments. Ethanol and Ro 25-6981 share similarities in exon 
use patterns with acute treatment and display differential exon expression in 
genes identified in AUD and MDD. Altered exon usage suggests differences in 
splicing, isoforms, and subsequently protein sequences and function177. Although 
we observed limited overlap in gene expression between ethanol and Ro 25-
6981 treatments, the abundant similarities in exon usage and genes containing 
DEEs suggests that shared alterations in protein function occur with both 
treatments. These co-occurring changes observed at 30 minutes might contribute 
to changes in synaptic function following induction of translation and activity of 
these new proteins, and be important for the initial antidepressant activity of 
ethanol. We highlighted two proteins where this might occur, NMDAR and 
ATP9B. NR1 acute expression displays increases in exon patterns thought to be 
involved in NMDAR function. ATP9B exon specific splicing is less well 
understood, but it is interesting that Ro 25-6981 increases some exons whereas 
MDD decreases others, identifying alternative splicing as an important avenue of 
research for the treatment of MDD or AUD.   
 Although we did not observe many parallel changes in gene expression, 
perhaps the DEGs we did discover had important protein interactions. We further 
assessed the 50 shared DEGs found with ethanol and Ro 25-6981 by comparing 
our gene expression results with key genes identified among our genes with 
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DEEs (NMDAR1, GABABR1, GABAAR5, ATP9B, and EIF3K) and found many 
protein-protein interactions important to predominant genes and pathways in the 
fields (Fig. 3.6). By using a protein network approach, we found that our DEGs 
(displayed in color) are related to key genes known to be important to AUD or 
MDD (displayed in red), and secondary interacting proteins (grey). DEGs that are 
highly connected may be important for downstream changes in other proteins 
with treatment, such as Rhob198 involved in GTP binding and GPCR signaling, 
and Dlg a scaffolding protein related to ion channel binding71. This network 
contains proteins involved in AUD and MDD as well as not well-characterized 
proteins. Even though few genes were similarly expressed with ethanol and Ro 
25-6981, many interact with key proteins and pathways of interest. This opens 
new avenues for exploring these targets with ethanol and/or rapid 
antidepressants.   
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Figure 3.6. Protein interaction network of DEGs and proteins of interest  
 
This protein interaction network is of the 50 simultaneously regulated DEGs 
between ethanol and Ro 25-6981 acute treatment. This network generated using 
String (version10.0) depicts the possible interactions of the 50 co-occurring 
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differentially expressed genes in addition to five proteins of interest important to 
AUD and MDD and found within the genes containing DEEs shown in red (Eif3k, 
Atp9b, Gabbr1, Grin1, and Gabra5). The 50 genes are shown in color while 
secondary shell interacting proteins are shown in grey. These secondary proteins 
may indicate pathways or interacting proteins of interest related to the DEGs we 
identified.  Line thickness indicates the strength of data to support the interaction.  
 
 
 Overall this work implicates alternative splicing as an important mechanism 
for altering synaptic function with acute treatment of alcohol or rapid 
antidepressants.  Parallel alterations in exon use were identified with ethanol and 
Ro 25-6981 treatment. This altered exon use likely contributes to the mechanism 
of Ro 25-6981 and other NMDAR antagonists providing important context for 
their biological and pharmacological implications. Some of these changes 
coincide with evidence of alternative splicing in human AUD and MDD. By 
examining different isoforms it may be possible to discover other targets to 
investigate underlying changes associated with the high comorbidity of AUD and 
MDD.  
 
CHAPTER 4: DISCUSSION 
 
The comorbidity between alcohol and psychiatric disorders is astounding14, 36; 
however very little is known about the molecular basis for this co-occurrence. 
This novel study identified that acute alcohol exposure elicits an antidepressant-
like behavior that can persist up to 24 hours after exposure, suggesting that 
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ethanol can initiate a lasting antidepressant response. Furthermore we found that 
ethanol has a shared molecular pathway with rapid antidepressant that may 
explain these phenomena. Rapid antidepressant and ethanol inhibit NMDAR52, 58, 
128, 175 activity and induce two key molecular changes that produce the observed 
antidepressant response, including (1) an increase in GABABR protein synthesis 
and (2) a shift in GABABR function that increases dendritic calcium signaling13, 78, 
79. Additionally, we identified FMRP as a key regulator of the induced protein 
synthesis of GABABR upon acute RAAD and ethanol exposure79.  Next we 
expanded our study by using RNA sequencing to identify synaptic changes on a 
more global scale that may be related to our pathway of interest. We identified a 
few select genes that displayed parallel expression changes with both acute 
ethanol and Ro 25-6981, suggesting that many acute ethanol changes are 
independent of NR2B inhibition. However, our findings suggested that exon use 
and alternative splicing may have a greater impact on the transcriptome with 
alcohol and RAAD exposure rather than differential gene expression.   
 Based on our data we proposed a mechanism from transcription to 
translation that could occur with acute ethanol and RAAD exposure. We envision 
two waves of translation occurring upon ethanol or RAAD exposure. The first 
wave would initiate translation of synaptic mRNAs already present at the 
synapse81, 82. These mRNAs would include those involved in the initiation of 
synaptic signaling and translation such as the GABABR213, 79 and mTOR61, 74. 
The second wave of translation would initiate protein translation of those 
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differentially expressed genes and exons identified with acute ethanol and Ro 25-
6981 exposure. These possible alternatively spliced transcripts may be 
translated, have non-canonical function or localization, and affect synaptic 
function. Further research is needed to identify the nature of these changes. 
 
 
Figure 4.1. Proposed model for the shared acute actions of ethanol and Ro 25-
6981  
 
Arrows in red represent data from chapter 2 in which NMDAR inhibition induces 
release of FMRP binding allowing translation of GABABR2 and new GABABRs 
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facilitate calcium entry and signaling to activate protein translation. Arrows in 
green represent data from chapter 3 in which NMDAR inhibition triggers 
alternative splicing/exon usage which leads to new translation of these new 
splice variants. Both these pathway lead to translation of alternative proteins and 
induction of synaptic plasticity.   
 
Limitations 
 
Some limitations of our study exist that could be addressed in the future. One is 
that we only explored pathways in the hippocampus. We focused on alterations 
in the hippocampus due to previous studies of ethanol and antidepressants 
affecting this brain region in both humans and animals60, 113, 95. Additionally, our 
previous work identified molecular mechanisms induced by Ro 25-6981 as well 
as other NMDAR inhibitors in the hippocampus79. However, it would be 
interesting to identify if this pathway is conserved between brain regions. We 
would also like to ask if other NMDAR antagonist such as Ketamine have the 
same effect as Ro 25-6981. We chose Ro 25-6981 for it’s highly selective and 
potent inhibition of the NR2B subunit of the NMDAR31, 32, as opposed to other 
rapid antidepressants that have adverse side effects27, or alternative convoluting 
mechanisms of action175. However, disadvantages to using Ro 25-6981 are that 
it is not FDA approved and further away from being a pharmaceutical treatment 
option. We also limited our experiments to an acute time point for feasibility, but 
extending our findings from acute to chronic and withdrawal would give further 
insight into the development of the initial use of alcohol to lasting chronic use and 
addiction.  
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Future Direction 
 
Several avenues of interest emerge from this research for future studies 
including neuroadaptive changes with chronic and withdrawal alcohol use, further 
characterization of the antidepressant effects of alcohol, and continued 
exploration of splice patterning in AUD and MDD.  
Future directions will test the hypothesis that regulation of GABABR 
function will contribute to dendritic neuroadaptation from acute to chronic and 
withdrawal ethanol states. Preliminary results suggest that dendritic GABABR 
expression decreases with chronic exposure, and increases with ethanol 
withdrawal. We propose that GABABR signaling is differentially regulated with 
acute, chronic, and withdrawal ethanol to regulate protein translation and 
synaptic protein composition; causing or counteracting neuroadaptations that 
occur with ethanol62, 94. Downstream changes in synaptic protein composition 
and synaptic plasticity induced by activation of this antidepressant pathway13, 78, 
79 would be interesting to explore at chronic and withdrawal states of 
antidepressant and ethanol use. This data would further our understanding of the 
mechanisms of this pathway and the behaviors they provoke. Further research 
on mechanisms of comorbidity may reveal new targets for the development of 
comorbid treatments, and eventually aid in development of much needed 
therapeutic options for individuals with dual diagnosis.  
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One immediate question that comes to rise is how does one dose of ethanol or 
RAAD induce the lasting antidepressant like effect we observed, and how long 
does that effect last. Studies with the rapid antidepressant Ketamine have 
varying results, but identified Ketamine as eliciting an antidepressant effect for up 
to a week in behavioral test for antidepressant efficacy70, 71, 199. The mechanism 
for action for this lasting effect of Ketamine are still under scrutiny, but focus on a 
cascade of neurochemical events initiated immediately after treatment26. It would 
be of interest to expand our shared molecular changes by first interrogating these 
potential neurochemical events since Ketamine, ethanol, and Ro 25-6981 all 
induce changes via NMDAR inhibition. We could predict that Ketamine changes 
such as activation of mTOR dependent pathways74 and BDNF73 would be 
conserved with acute treatment of ethanol and Ro 25-6981, and may increase 
our understanding of the actions of Ketamine as well. Additionally, we would like 
to see if ethanol and/or Ro 25-6981 elicit an antidepressant like response for up 
to a week, and the time of onset of the antidepressant effects. This will further 
characterize the self-medication effect, by identifying if more alcohol 
administration is needed to maintain an antidepressant like response.  This 
progressive increase in alcohol consumption may lead to increased alcohol 
abuse and dependence101. 
 Numerous targets for further exploration are present in our RNA-seq data 
for ethanol, antidepressant, or shared molecular changes. Here we took a 
particular interest in NMDAR1 and ATP9B exon usage and their implications for 
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protein and synaptic function, but other targets such as GABABR1, GABAAR, and 
EIF3K and numerous others of interest to the field. Additionally, novel targets of 
interest can be identified for further exploration. It will be important to identify if 
altered exon use and thus splicing occurs in protein domains that will affect their 
function or localization and/or cellular function200. An immediate next step is to 
verify that these proposed spliceforms are translated, when they are translated, 
and if their respective alteration in expression is lasting. Translation and function 
of these isoforms may play a role in the lasting antidepressant effects of ethanol 
and Ro 25-6981. We did identify differentially expressed exons in genes 
previously shown to be involved in AUD and MDD. Pairing our results with an 
animal model of depression may be revealing. By exploring similarities and 
differences in an animal model of depression with and without ethanol or Ro 25-
6981 expression we may find increasing evidence of splice variants and their role 
in AUD and MDD.  
Conclusion 
AUD and MDD are two devastating and complex disorders, and have been 
closely linked through epidemiological and clinical studies14, 36. but the high rate of 
comorbidity is not well understood. These results indicate that an underlying 
mechanism may increase the likelihood of developing comorbid AUD and MDD, 
and possibly other psychiatric disorders and substance abuse disorders. Further 
research is need to identify the extent of the molecular changes that we observed 
with ethanol and Ro 25-6981, and how downstream changes induced by this 
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pathway affect synaptic plasticity, neuroadaptation, and behavior. Additionally it 
will be imperative to assess the effects of alternative splicing with acute alcohol 
and RAADs. Specifically, do the splice events we identified acutely lead to 
neuroadaptation, produce lasting alterations in synaptic protein composition, or 
alter functions at the synapse and thus behavior? Other shared molecular 
changes may also exist between RAADs and ethanol that may further our 
understanding of comorbidity. Our research implicates several pathways and 
genes of interest for further investigation, including those targetable for potential 
therapeutic avenues.  
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SUPPLEMENTARY FIGURES 
 
Supplemental Figure 2.1. Working model of ethanol-induced GABABR plasticity 
 
Under normal conditions (on left) FMRP represses translation of target mRNA 
(e.g., GABABR2), and GABABR signaling is inhibitory via activation of G-protein 
inwardly rectifying potassium channels (Kir3/GIRK) in dendrites. Ethanol 
exposure (on right) inhibits NMDARs, causing FMRP to release GABABR2 
mRNA, allowing for its translation. Newly synthesized GABABR2 assembles as a 
functional heterodimer with GABABR1 and is transported to the dendritic 
membrane. Upon activation, new surface GABABRs facilitate calcium channel 
activity and may activate mTOR.  
  
K+
Na+Ca
2+
N N
GABA  RB NMDAR
Channel
Ca2+
FMRP
ER
Translational  
Repression
FMRP
Translation
ER
N N
New GABA  RB
NN
Ca2+
NMDAR
Channel
Ca2+
Ethanol
Ethanol Normal Conditions
Dendritic  
Membrane
GIRK
K+
mTOR
GIRK
GABA  RB
Ca2+ Channel
NMDAR
FMRP
GABA  R1B GABA  R1B GABA  R2B
Supplementary Figure 1. Working model of ethanol-induced GABABR plasticity 
Under normal conditions (on left) FMRP represses translation of target mRNA (e.g., 
GABABR2), and GABABR signaling is inhibitory via activation of G-protein inwardly 
rectifying potassium channels (Kir3/GIRK) in dendrites. Ethanol exposure (on right) 
inhibits NMDARs, causing FMRP to release GABABR2 mRNA, allowing for its 
translation. Newly synthesized GABABR2 assembles as a functional heterodimer with 
GABABR1 and is transported to the dendritic membrane. Upon activation, new surface 
GABABRs facilitate calcium chan el activit and may activate mTOR.  
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Supplemental Figure 2.2. Dendritic caliber is unaffected by acute ethanol 
 
a) The width of cultured hippocampal dendrites proximal to the soma was 
measured using ImageJ software, and no significant changes in dendrite caliber 
were observed. Veh=2.38 ± 0.14 µm, n=28 dendrites; ETOH=2.18 ± 0.17 µm, 
n=38 dendrites; values represent mean ± SEM.  
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Supplementary Figure 2. Dendritic calib r is unaffe ted by acute ethanol 
The width of cultured hippocampal dendrites proximal to the soma was measured 
using ImageJ software, and no significant changes in dendrite caliber were observed. 
Veh=2.38 ± 0.14 µm, n=28 dendrites; ETOH=2.18 ± 0.17 µm, n=38 dendrites; values 
represent mean ± SEM.
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Supplemental Figure 2.3. Ro 25-6981 reduces dendritic expression of FMRP  
 
(a) Representative immunofluorescent images and (b) summary graph of 
dendrites from cultured hippocampal neurons treated with Ro 25-6981 (10 µM, 2 
hours) showing decreased dendritic FMRP expression (0.54 ± 0.04, n=40 
dendrites) compared to vehicle (Veh)-treated neurons (H2O, 2 hours; 1.00 ± 0.05, 
n=49 dendrites) normalized to MAP2. Significance determined by Student's t-
test. Values represent mean ± SEM. Scale bar=5 µm.  
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Supplementary Figure 3. Ro 25-6981 reduces dendritic expression of FMRP  
(a) Representative immunofluorescent images and (b) summary graph of dendrites from 
cultured hippocampal neurons treated with Ro 25-6981 (10 µM, 2 hours) showing 
decreased dendritic FMRP expression (0.54 ± 0.04, n=40 dendrites) compared to 
vehicle (Veh)-treated neurons (H2O, 2 hours; 1.00 ± 0.05, n=49 dendrites) normalized to 
MAP2. Significance determined by Student's t-test. Values represent mean ± SEM. 
Scale bar=5 µm.  
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Supplemental Figure 2.4. Excess FMRP represses ethanol-induced GABABR 
plasticity 
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Supplementary Figure 4. Exces   repres es etha ol -induced GABABR 
plasticity 
(a-c) Mouse hippocampal cultured neurons were pretreated for 2 hours with vehicle 
(Veh: H2O) or ethanol (ETOH: 30 mM). Line graphs represent the average fluorescent 
calcium signal over time in dendrites from (a) wildtype and (b) Fmr1 KO mice. Baseline 
was established for 1 minute before the addition of vehicle and equilibrated as indicated 
by the break between dotted lines. (c) Summary graph shows that calcium remains at 
baseline in dendrites imaged ( F/F) in wildtype (WT) and Fmr1 KO neurons treated with 
vehicle or ethanol. WT: Veh+Veh=2.25 ± 2.29, n=14; ETOH+Veh=1.60 ± 0.71, n=24.  
Fmr1 KO : Veh+Veh=-2.50 ± 1.05, n=12; ETOH+Veh=0.64 ± 1.68, n=12. Related to 
Figure 7a-c. (d-e) Dendritic calcium imaging in hippocampal cultured neurons infected 
with vector (rAAV:mSYN-tdTomato) or showing FMRP overexpression (rAAV:mSYN-
FMRP and rAAV:mSYN-tdTomato). Line graph illustrates the average fluorescent 
calcium signal in (d) vector and (e) FMPR overexpressing neurons pre-treated for 2 
hours with vehicle or ethanol. Ethanol-induced increase in dendritic calcium is blocked 
by FMRP overexpression. Related to Figure 7d. Significance determined by two-way 
ANOVA and Tukey’s multiple comparison test. Values represent mean ± SEM. 
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(a-c) Mouse hippocampal cultured neurons were pretreated for 2 hours with 
vehicle (Veh: H2O) or ethanol (ETOH: 30 mM). Line graphs represent the 
average fluorescent calcium signal over time in dendrites from (a) wildtype and 
(b) Fmr1 KO mice. Baseline was established for 1 minute before the addition of 
vehicle and equilibrated as indicated by the break between dotted lines. (c) 
Summary graph shows that calcium remains at baseline in dendrites imaged 
(ΔF/F) in wildtype (WT) and Fmr1 KO neurons treated with vehicle or ethanol. 
WT: Veh+Veh=2.25 ± 2.29, n=14; ETOH+Veh=1.60 ± 0.71, n=24.  Fmr1 KO : 
Veh+Veh=-2.50 ± 1.05, n=12; ETOH+Veh=0.64 ± 1.68, n=12. Related to Figure 
7a-c. (d-e) Dendritic calcium imaging in hippocampal cultured neurons infected 
with vector (rAAV:mSYN-tdTomato) or showing FMRP overexpression 
(rAAV:mSYN-FMRP and rAAV:mSYN-tdTomato). Line graph illustrates the 
average fluorescent calcium signal in (d) vector and (e) FMPR overexpressing 
neurons pre-treated for 2 hours with vehicle or ethanol. Ethanol-induced increase 
in dendritic calcium is blocked by FMRP overexpression. Related to Figure 7d. 
Significance determined by two-way ANOVA and Tukey’s multiple comparison 
test. Values represent mean ± SEM. 
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Supplemental Figure 2.5. GABABR elevates dendritic Ca2+ with ethanol and  
Ro 25-6981 
 
Calcium imaging in dendrites from rat hippocampal neurons. (a) Summary graph 
of ΔF/F of dendritic calcium in vehicle- (Veh: H2O) and ethanol- (ETOH: 30 mM) 
treated neurons for 2 hours with the addition of vehicle or baclofen (Bac, 50 µM). 
ΔF/F between vehicle and ethanol do not significantly change relative to 
baseline. Baclofen decreases dendritic calcium in vehicle-treated neurons but not 
in ethanol-treated neurons. Veh+Veh=- 0.007 ± 0.004, n=11; Veh+Bac=-0.05 ± 
0.01, n=11; ETOH+Bac=0.004 ± 0.02, n=12. Significance determined by one-way 
ANOVA with Dunnett’s multiple comparison test. Values represent mean ± SEM. 
(b) Summary graph of dendritic calcium in neurons pre-treated with either vehicle 
(Veh: H2O, 2 hours) or Ro 25-6981 (Ro; 10 µM, 2 hours) in the presence of 
vehicle or baclofen (Bac, 50 µM). Baclofen reduces the calcium signal in vehicle-
treated neurons but produces no significant change over baseline in the Ro 25-
6981-treated neurons. Veh+Veh=-0.01 ± 0.02, n=10; Veh+Bac=-0.09 ± 0.02, 
n=9; Ro 25-698+Bac=0.01 ± 0.02, n=8. Significance determined by one-way 
ANOVA and Dunnett’s multiple comparison test. Values represent mean ± SEM. 
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Supplementary Figure 5. GABABR elevates dendritic Ca2+ with ethanol and  
Ro 25-6981 
 
Calcium imaging in dendrites from rat hippocamp l n uro s. (a) Summary graph of 
F/F of dendritic calcium in vehicle- (Veh: H2O) and ethanol- (ETOH: 30 m  treated 
neurons for 2 hours with the additio  f vehicle or baclofen (Bac, 50 µM). F/F between 
vehicl  and ethanol o not ignificantly change relative to bas line. Baclofen decreases 
de dritic calcium i  vehicle-treated neurons but not in ethanol-treated neurons. 
Veh+Veh=- 0.007 ± 0.004, n=11; Veh+Bac=-0.05 ± 0.01, n=11; ETOH+Bac=0.004 ± 
0.02, n=12. Significance determined by one-way ANOVA with Dunnett’s multiple 
comparison test. Values represent mean ± SEM. (b) Summary graph of dendritic 
calcium in neurons pre-treated with either vehicle (Veh: H2O, 2 hours) or Ro 25-6981 
(Ro; 10 µM, 2 hours) in the presence of vehicle or baclofen (Bac, 50 µM). Baclofen 
reduces the calcium signal in vehicle-treated neurons but produces no significant 
change over baseline in the Ro 25-6981-treated neurons. Veh+Veh=-0.01 ± 0.02, n=10; 
Veh+Bac=-0.09 ± 0.02, n=9; Ro 25-698+Bac=0.01 ± 0.02, n=8. Significance determined 
by one-way ANOVA and Dunnett’s multiple comparison test. Values represent mean ± 
SEM. 
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Supplemental Figure 2.6. Ethanol’s antidepressant effect is absent in Fmr1 KO 
 
Fmr1 KO mice subjected to the splash test displayed no behavioral differences in 
(a) groom time or (b) latency to initiate grooming 24 hours post-ethanol (ETOH: 
2.5 g kg-1, i.p.) compared to vehicle (Veh; saline, i.p.) treatment. Data from 
wildtype (WT) C57BL/6 mice from Fig. 1b and c are shown as the mean 
(horizontal dotted lines) ± SEM (horizontal shaded area in v=Veh=grey or 
ETOH=pink). Data for Fmr1 KO as indicated in bar graph (Veh=black or 
ETOH=red): Total groom time: Veh=3.44 ± 2.43 s, n=5; ETOH=1.20 ± 0.32 s, 
n=5. Latency to groom: Veh=297.0 ± 3.05 s, n=5; ETOH=300 ± 0.0 s, n=5. (c-e) 
Total center time, speed, and distance were measured in the open field test 24 
hours post-injection in Fmr1 KO mice. Ethanol-treated (2.5 g kg-1, i.p.) Fmr1 KO 
mice lacked the ethanol-induced increase in center time seen in WT mice (data 
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Supplementary Figure 6. Ethanol’s antidepressant effect is absent in Fmr1 KO 
Fmr1 KO mice subjected to the splash test displayed no behavioral differences in (a) groom 
time or (b) latency to initiate grooming 24 hours po t-ethanol (ETOH: 2.5 g kg-1, i.p.) compared 
to vehicle (Veh; saline, i.p.) treatment. Data from wildtype (WT) C57BL/6 mice from Fig. 1b and 
c are show  as th  mean (horizontal dotted lines) ± SEM (horizontal shaded area in 
v=Veh=grey or ETOH=pink). Data for Fmr1 KO as indicated in bar graph (Veh=black or 
ETOH=red): Total gr om time: Veh=3.44 ± 2. 3 s, n=5; ETOH=1.20 ± 0.32 s, n=5. Latency to 
groom: Veh=297.0 ± 3.05 s, n=5; ETOH=30  ± 0.0 s, n=5. (c-e) Total center time, speed, and 
distance were m asur d in the open f eld test 24 hours post-injection in Fmr1 KO mice. Ethanol-
treated (2.5 g kg-1, i.p.) Fmr1 KO mice lacked the ethanol-induced increase in center time seen 
in WT i  (data tak n from Fig. 1b and ). Speed a d distance traveled of Fmr1 KO mice were 
unaffected by ethanol treatment, but both measures were increased compared to WT due to 
hyperexcitability in Fmr1 KO mice. Total center time: Veh=401.6 ± 22.01 s, n=6; ETOH=377.4 ± 
64.24 s, n=6. Average speed: Veh=0.05 ± 0.003 m/s, n=6; ETOH=0.06 ± 0.006 m/s, n=6. Total 
distance: Veh=95.89 ± 5.24 m, n=6; ETOH=104.4 ± 10.79 m, n=6. Significance determined by 
one-tailed t-test. Significance between genotypes designated by #. Average speed total: WT-
Veh vs. KO-Veh P=0.006, WT-ETOH vs. KO-ETOH P=0.010. Distance: WT-Veh vs. KO-Veh 
P=0.005, WT-ETOH vs. KO-ETOH P=0.009. Values represent mean ± SEM. 
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taken from Fig. 1b and c). Speed and distance traveled of Fmr1 KO mice were 
unaffected by ethanol treatment, but both measures were increased compared to 
WT due to hyperexcitability in Fmr1 KO mice. Total center time: Veh=401.6 ± 
22.01 s, n=6; ETOH=377.4 ± 64.24 s, n=6. Average speed: Veh=0.05 ± 0.003 
m/s, n=6; ETOH=0.06 ± 0.006 m/s, n=6. Total distance: Veh=95.89 ± 5.24 m, 
n=6; ETOH=104.4 ± 10.79 m, n=6. Significance determined by one-tailed t-test. 
Significance between genotypes designated by #. Average speed total: WT-Veh 
vs. KO-Veh P=0.006, WT-ETOH vs. KO-ETOH P=0.010. Distance: WT-Veh vs. 
KO-Veh P=0.005, WT-ETOH vs. KO-ETOH P=0.009. Values represent mean ± 
SEM. 
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Supplemental Figure 2.7. Full uncropped images for representative blots 
 
Full Western blots for all representative images are shown. Blots were cut to 
optimize staining. (a) Western blot for (a1) GABABR1, (a2) GABABR2, and 
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Supplementary Figure 7. Full uncropped images for representative blots 
Full Western blots for all representative images are shown. Blots were cut to optimize staining. 
(a) Western blot for (a1) GABABR1, (a2) GABABR2, and corresponding (a3) -Tubulin are 
shown for Figure 2. (a1-3) Blot was probed for (a1) rabbit anti-GABABR1 and (a2) mouse anti-
GABABR2 simultaneously and imaged with Licor Odyssey imaging system. Prior to Western blot 
membrane was cut just below 75kD and probed for (a3) -Tubulin. (b) Western blot of (b1) 
GABABR1, (b2) GABABR2, and corresponding (b3) -Tubulin; and (b5) FMRP and 
corresponding (b4) -Tubulin are shown for Figure 3. (b1-3) Blot was probed for (b1) rabbit anti-
GABABR1 and (b2) mouse anti-GABABR2 simultaneously and was cut just below 75kD and 
probed for (b3) -Tubulin. (b5-6) Western blot was probed for (b5) FMRP and cut and probed 
below 75kD for (b6) -Tubulin. (c) Western blot for GABABR1, GABABR2, and corresponding -
Tubulin in WT and Fmr1 KO mice are shown for Figure 5. (c1-3) Blot was probed for (c1) rabbit 
anti-GABABR1 and (c2) mouse anti-GABABR2 simultaneously and was cut just below 75kD and 
probed for (c3) -Tubulin. Molecular weight marker is shown to the left of all images. (d1-2) Full 
representative gels showing RT-qPCR amplified product of input sample, FMRP RIP, and IgG 
control are shown for (d1) GABABR1 and (d2) GABABR2. 
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corresponding (a3) α-Tubulin are shown for Figure 2. (a1-3) Blot was probed for 
(a1) rabbit anti-GABABR1 and (a2) mouse anti-GABABR2 simultaneously and 
imaged with Licor Odyssey imaging system. Prior to Western blot membrane was 
cut just below 75kD and probed for (a3) α-Tubulin. (b) Western blot of (b1) 
GABABR1, (b2) GABABR2, and corresponding (b3) α-Tubulin; and (b5) FMRP 
and corresponding (b4) α-Tubulin are shown for Figure 3. (b1-3) Blot was probed 
for (b1) rabbit anti-GABABR1 and (b2) mouse anti-GABABR2 simultaneously and 
was cut just below 75kD and probed for (b3) α-Tubulin. (b5-6) Western blot was 
probed for (b5) FMRP and cut and probed below 75kD for (b6) α-Tubulin. (c) 
Western blot for GABABR1, GABABR2, and corresponding α-Tubulin in WT and 
Fmr1 KO mice are shown for Figure 5. (c1-3) Blot was probed for (c1) rabbit anti-
GABABR1 and (c2) mouse anti-GABABR2 simultaneously and was cut just below 
75kD and probed for (c3) α-Tubulin. Molecular weight marker is shown to the left 
of all images. (d1-2) Full representative gels showing RT-qPCR amplified product 
of input sample, FMRP RIP, and IgG control are shown for (d1) GABABR1 and 
(d2) GABABR2. 
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Supplemental Figure 3.1. Synaptoneurosomal enrichment analysis 
 
The top 500 most abundant genes identified from the average normalized counts 
of RNA sequenced from saline (n=8) treated C57Bl/6 mice were analyzed for 
synaptic enrichment as a control for synaptoneurosome isolation. Cellular 
component gene ontologies for these 500 most abundant genes were identified 
with Enrichr gene enrichment analysis tool. The 5 most significant ontologies 
determined by p value are shown in the summary bar graphs, all are synaptic 
related.  
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Supplemental Figure 3.2. Principle component analysis (PCA) of saline, ethanol 
and Ro 25-6981 
 
a) PCA for vehicle (saline; blue, n=8) and ethanol (red, n=7) treatment shows no 
batch effect differences or outliers between samples. b) PCA for vehicle (saline; 
blue, n-8) and Ro 25-6981 (red, n=8) treatment shows now batch effect 
differences or outliers between samples. 
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Ro = Ro 25-6981 (10mg/kg) 
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Supplemental Figure 3.3. Hierarchical cluster and correlation plot of all samples 
 
a) Hierarchical cluster of samples indicates that there are no outliers (saline, n=8; 
ethanol, n=7; Ro 25-6981, n=8). b) Correlation plot of gene count per sample 
indicate no outliers, number indicates correlation coefficient between samples, 
scale coincides with correlation coefficient from 0 (white) to 1 (blue).  
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Supplemental Figure 3.4.  Up-regulated and down-regulated genes with Ro 25-
6981 acute treatment  
 
Summary bar graph indicates the top 10 up- and down- regulated DEGs 
according to log2fold change identified with acute Ro 25-6981 DEGs (p ≤ 0.05). 
Blue indicates down-regulated while red indicates up-regulated fold changes. 
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Supplemental Figure 3.5. Volcano plots of exons identified with DEXSeq with 
ethanol and Ro 25-6981 treatment  
 
a) Volcano plot of differentially expressed exons with ethanol (n=7) compared to 
vehicle (saline, n=8) reveal a significant number of exons (red) both up- and 
down-regulated with ethanol exposure shown as positive of negative log2fold 
change with treatment (p ≤ 0.05). b) Volcano plot of differentially expressed 
exons with Ro 25-6981 compared to vehicle reveal a significant number of exons 
(yellow) both up- and down-regulated with Ro 25-6981 exposure shown as 
positive of negative log2fold change with treatment (p ≤ 0.05).  
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